var title_f35_59_36784="Advanced tennis forehand grip";
var content_f35_59_36784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Advanced tennis forehand grip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jayanthi N, Subbarao JV. Racket sports injuries. In: Sports Medicine and Rehabilitation: A Sports Specific Approach. Buschbacher R, Prahlow N, Dave SJ (eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36784=[""].join("\n");
var outline_f35_59_36784=null;
var title_f35_59_36785="Tuberculous pleurisy";
var content_f35_59_36785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary tuberculosis in pregnant woman",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large right sided pleural effusion with typical meniscoid arc and with extension into the major fissure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36785=[""].join("\n");
var outline_f35_59_36785=null;
var title_f35_59_36786="Squamous cell carcinoma - lip";
var content_f35_59_36786=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma on the lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This erythematous, crusted nodule on the lip represents a squamous cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36786=[""].join("\n");
var outline_f35_59_36786=null;
var title_f35_59_36787="Factors for TIMI grade flow";
var content_f35_59_36787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Schematic of factors potentially influencing TIMI grade flow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are a number of factors, acting in concert, that determine the patency of the coronary artery after thrombolysis; these include hemodynamics, local artery anatomy, the thrombus, cellular mechanisms, and procedural issues. The TIMI flow grade, which has been determined at various points in time after thrombolysis, correlates with mortality after the infarction. (With permission from Tan WA, Noliterno DJ. Am Heart J 1998; 136:570).",
"    <div class=\"footnotes\">",
"     <br>",
"      *DPB=diastolic blood pressure, EDP=left ventricular end-diastolic pressure",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36787=[""].join("\n");
var outline_f35_59_36787=null;
var title_f35_59_36788="Hydroquinone: Drug information";
var content_f35_59_36788=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroquinone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/43/15028?source=see_link\">",
"    see \"Hydroquinone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aclaro PD&reg;;",
"     </li>",
"     <li>",
"      Aclaro&reg;;",
"     </li>",
"     <li>",
"      Alphaquin HP&reg;;",
"     </li>",
"     <li>",
"      Eldopaque Forte&reg;;",
"     </li>",
"     <li>",
"      Eldopaque&reg; [OTC];",
"     </li>",
"     <li>",
"      Eldoquin Forte&reg;;",
"     </li>",
"     <li>",
"      Eldoquin&reg; [OTC];",
"     </li>",
"     <li>",
"      EpiQuin&reg; Micro;",
"     </li>",
"     <li>",
"      Esoterica&reg; Daytime [OTC];",
"     </li>",
"     <li>",
"      Esoterica&reg; Nighttime [OTC];",
"     </li>",
"     <li>",
"      Lustra-AF&reg;;",
"     </li>",
"     <li>",
"      Lustra-Ultra&trade;;",
"     </li>",
"     <li>",
"      Lustra&reg;;",
"     </li>",
"     <li>",
"      Melpaque HP&reg;;",
"     </li>",
"     <li>",
"      Melquin HP&reg;;",
"     </li>",
"     <li>",
"      Melquin-3&reg;;",
"     </li>",
"     <li>",
"      NeoStrata&reg; HQ Skin Lightening [OTC];",
"     </li>",
"     <li>",
"      Nuquin HP&reg;;",
"     </li>",
"     <li>",
"      Palmer's&reg; Skin Success&reg; Eventone&reg; Fade Cream [OTC];",
"     </li>",
"     <li>",
"      Palmer's&reg; Skin Success&reg; Eventone&reg; Fade Milk [OTC];",
"     </li>",
"     <li>",
"      Palmer's&reg; Skin Success&reg; Eventone&reg; Ultra Fade Serum [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eldopaque&reg;;",
"     </li>",
"     <li>",
"      Eldoquin&reg;;",
"     </li>",
"     <li>",
"      Glyquin&reg; XM;",
"     </li>",
"     <li>",
"      Lustra&reg;;",
"     </li>",
"     <li>",
"      NeoStrata&reg; HQ;",
"     </li>",
"     <li>",
"      Solaquin Forte&reg;;",
"     </li>",
"     <li>",
"      Solaquin&reg;;",
"     </li>",
"     <li>",
"      Ultraquin&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F180698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Depigmenting Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F180683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bleaching: Topical: Apply a thin layer and rub in twice daily.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F180691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F180684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 4% (28.35 g, 28.4 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alphaquin HP&reg;: 4% (28.4 g, 56.7 g) [contains sodium metabisulfite, sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eldopaque Forte&reg;: 4% (28.35 g) [contains sodium metabisulfite, sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eldopaque&reg;: 2% (28.35 g) [contains sodium metabisulfite, sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eldoquin Forte&reg;: 4% (28.4 g) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eldoquin&reg;: 2% (28.35 g) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EpiQuin&reg; Micro: 4% (30 g, 40 g [DSC]) [contains benzyl alcohol, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Esoterica&reg; Daytime: 2% (85 g) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Esoterica&reg; Daytime: 2% (70 g) [contains sodium metabisulfite, sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Esoterica&reg; Nighttime: 2% (85 g) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lustra-AF&reg;: 4% (56.8 g) [contains benzyl alcohol, ethanol, sodium metabisulfite, sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lustra-Ultra&trade;: 4% (56.8 g) [contains sodium metabisulfite, sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lustra&reg;: 4% (56.8 g) [contains benzyl alcohol, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Melpaque HP&reg;: 4% (14.2 g, 28.4 g) [contains sodium metabisulfite, sunblock]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Melquin HP&reg;: 4% (14.2 g, 28.4 g) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nuquin HP&reg;: 4% (14.2 g, 28.4 g, 56.7 g) [contains ethanol, sodium metabisulfite, sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Palmer's&reg; Skin Success&reg; Eventone&reg; Fade Cream: 2% (75 g) [contains sodium sulfite, sunscreen; dry skin formula]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Palmer's&reg; Skin Success&reg; Eventone&reg; Fade Cream: 2% (75 g) [contains sodium sulfite, sunscreen; oily skin formula]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Palmer's&reg; Skin Success&reg; Eventone&reg; Fade Cream: 2% (75 g, 125 g) [contains sodium sulfite, sunscreen; regular skin formula]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aclaro PD&reg;: 4% (42.5 g) [contains benzyl alcohol, sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aclaro&reg;: 4% (48.2 g) [contains benzyl alcohol, sodium metabisulfite, sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 4% (28.35 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeoStrata&reg; HQ Skin Lightening: 2% (30 g) [contains ethanol, sodium bisulfite, sodium sulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nuquin HP&reg;: 4% (14.2 g, 28.4 g) [contains ethanol, sodium metabisulfite, sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Palmer's&reg; Skin Success&reg; Eventone&reg; Fade Milk: 2% (250 mL) [contains corn oil, sodium metabisulfite, sodium sulfite, sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Melquin-3&reg;: 3% (29.57 mL) [contains ethanol 45%, isopropyl alcohol 4%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Palmer's&reg; Skin Success&reg; Eventone&reg; Ultra Fade Serum: 2% (30 mL) [contains corn oil, shea nut derivatives, sodium metabisulfite, sodium sulfite, sunscreen]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     For external use only; avoid contact with eyes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F180670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gradual bleaching of hyperpigmented skin conditions",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F180704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Eldopaque&reg; may be confused with Eldoquin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Eldopaque Forte&reg; may be confused with Eldoquin Forte&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F180696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, dryness, erythema, stinging, inflammatory reaction, sensitization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F180673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroquinone or any component of the formulation; sunburn, depilatory usage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F180661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Limit application to area no larger than face and neck or hands and arms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F180665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F180666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with topical administration; the amount of systemic absorption is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F180686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16570936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if hydroquinone is excreted in breast milk. The manufacturer recommends that caution be exercised when administering hydroquinone to nursing women",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F180674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Alphaquin HP External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (28.4 g): $44.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Eldopaque External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (28.35 g): $28.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Eldopaque Forte External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (28.35 g): $59.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Eldoquin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (28.35 g): $28.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Eldoquin Forte External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (28.35 g): $59.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (EpiQuin Micro External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (30 g): $158.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Esoterica Facial External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (85 g): $6.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Esoterica Fade Nighttime External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (70 g): $6.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Esoterica Sensitive Skin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5% (85 g): $6.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Hydroquinone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (28.35 g): $45.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lustra External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (56.8 g): $144.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lustra-AF External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (56.8 g): $158.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lustra-Ultra External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (28.4 g): $95.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (NAVA-SC External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (28.4 g): $39.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Remergent HQ External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (30 mL): $80.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Aclaro External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (48.2 g): $187.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Aclaro PD External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (42.5 g): $149.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Melquin 3 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (29.57 mL): $22.85",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F180675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aldoquin (CO);",
"     </li>",
"     <li>",
"      Claripel (AR);",
"     </li>",
"     <li>",
"      Clasifel (PY, UY);",
"     </li>",
"     <li>",
"      Crema Blanca Bustillos (MX);",
"     </li>",
"     <li>",
"      Cremoquinona (CO);",
"     </li>",
"     <li>",
"      Delanin (TH);",
"     </li>",
"     <li>",
"      Domina (HK);",
"     </li>",
"     <li>",
"      Eldopaque (AE, BH, CY, EG, GR, IQ, IR, JO, KW, LB, LY, OM, PE, PH, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Eldopaque Forte (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PH, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Eldoquin (AE, BH, CR, CY, EG, GT, HK, HN, IQ, IR, JO, KW, LB, LY, MX, NI, OM, PA, PE, PH, PK, PT, QA, SA, SV, SY, YE);",
"     </li>",
"     <li>",
"      Eldoquin Cream (NZ);",
"     </li>",
"     <li>",
"      Eldoquin Forte (AE, BH, CY, EG, HK, IQ, IR, JO, KW, LB, LY, OM, PH, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Eslite (IN);",
"     </li>",
"     <li>",
"      Esomed (IL);",
"     </li>",
"     <li>",
"      Etnoderm (CN);",
"     </li>",
"     <li>",
"      Filtroquinona (DO, EC, GT, HN, PA, SV);",
"     </li>",
"     <li>",
"      Gentleclean (TW);",
"     </li>",
"     <li>",
"      Ginomi (KP);",
"     </li>",
"     <li>",
"      Laviquin (KP);",
"     </li>",
"     <li>",
"      Melanox (ID);",
"     </li>",
"     <li>",
"      Melashine (MY);",
"     </li>",
"     <li>",
"      Melquin HP (KP);",
"     </li>",
"     <li>",
"      Melquine (TW);",
"     </li>",
"     <li>",
"      Pharquinon (VE);",
"     </li>",
"     <li>",
"      Pigmentasa (ES);",
"     </li>",
"     <li>",
"      Polyquin Forte (SG);",
"     </li>",
"     <li>",
"      Qian Bai (CL);",
"     </li>",
"     <li>",
"      Solaquin (AE, BH, BR, CY, EG, HK, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Solaquin Forte (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Zumae (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F180660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces reversible depigmentation of the skin by suppression of melanocyte metabolic processes, in particular the inhibition of the enzymatic oxidation of tyrosine to DOPA (3,4-dihydroxyphenylalanine); sun exposure reverses this effect and will cause repigmentation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F180672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset and duration of depigmentation produced by hydroquinone varies among individuals",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8539 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36788=[""].join("\n");
var outline_f35_59_36788=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180680\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180681\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180698\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180683\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180691\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180684\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180669\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180657\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803133\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180670\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180704\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180696\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180673\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180661\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299482\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180665\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180666\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206272\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180686\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570936\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180674\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180675\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180660\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180672\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8539\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8539|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/43/15028?source=related_link\">",
"      Hydroquinone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_59_36789="Dietary questionnaire";
var content_f35_59_36789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Dietary questionnaire",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 708px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Permission to reproduce from: Nutrition During Pregnancy and Lactation: An Implementation Guide by Subcommittee for Institute of Medicine. 1992, p. 506. Copyright by National Academy Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36789=[""].join("\n");
var outline_f35_59_36789=null;
var title_f35_59_36790="TTTS4";
var content_f35_59_36790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63614%7EOBGYN%2F66239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63614%7EOBGYN%2F66239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TTTS4",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Donor twin with marked oligohydramnios at 24 2/7 weeks of gestation. Arrow denotes the membrane which can be seen extending between the lower fetal abdomen and the fetal thigh. The difficulty is finding this membrane can often lead to the erroneous diagnosis of monoamniotic twins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TTTS1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5YooooAKKKKACiiigAooooAKKKKACiiigAooooAKmtYJLq4jggUNLI21RkDJ+pqGvTvD3wuvNU8FjWkmjeWYFo4UYOVQdyAcg9ePSmgPO76wu9PvJbW+t5be5iOHikUqy/UVWOR1rr5ru5s1isvE1o2pWMeVjbeVmiB/uSf8AsrZFRTeGYNQRp/DF8L9erWcwEV0g/wB3OHHupP0osBylFS3ELQSGORWRxwVcYI/CoqVgCiiigAooooAKKWjFACUqgscCrmnabdahJstIHlIGWK9FHqT0H4133gP4dwa/qq2kmqWnnYJO6TZECO27qx+n50AedLbTGB5gh8pDhm7Z9Khr6T0yDwl4KW6MkcXiW/8AJe3ddgFtArDBA7Hr15NfO+qW8dtezRwHMIY7MnJA7ZptWEipRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSgZPFFaGkadNqGow2tuCzyHBIGdo7n8BQA7SdLuLxJJ4og8cJBYMfve1dBo2v6nod6tzo7yWM6H7mPXtzxivRV8AWJiR/CWrbiqhXhugY5C+PmOPeuV1jw9eWl1LFdwuxTl2V85HqM9qqwjRTxhpviBXTxJaGO/H33iUAN749fpWZf+CoLyQSaTMSzfNGYxkN6fQ1zt5BAkixxy+SQMeY64z702G91bS8tbXRaMnIkV8ii/cDRuJfEOnn7HrNtFqMUYx5N/DvZR04f7y9TjBrIkbw9cl/Mt77TZT08hhcRA554bDYx7muosfiTqKJCt/b2l/HCfuMmCR6Z6108Xi34T68q/294S1TSLrGGm02QMrH1Kk0rgeVXWl6e2TYa1bSgvtVZ4ngfH945BUfgxpJ/D10jRiK40+63rnMF2jAexyRg16k3/CNwOzeCp5bq0ZcNDqVtHuHuKy9Y8LWv20mWeytmkXfkrhR+Ap2uFzzxtA1FOXjgx/18R//ABVSNoUqWqTS3umpuz+7N0pdfqo6V2cek6BACt3f6ZgH5m8os5HqKsLF4Bt2jMWqSXG45kJt9hX6UrBc4+z8PwXMnlW93JeS7gAtnbMwIPX5mxg/ga6K38LHT5zDNpC/alGf9MkDkZ/2F4/Dmtg+PdB04iDQNOvZivAMrDEn4DoKp6p4n8Z6urGLToLK2Uc+TAFC+5Y85p2A27FL2Kxu47tIltI1DvHJiBPbgYz9BXKzaxYWrSu8X2lGXhfuhT6jBrLOmeJNeuUt1jvdQkY52qGeu88P/BTUZrQXfiXUI9Jtsj5JRgn2x2o8kB5/JdS6qMPIIIQNscUOcn2wOtdPofws1PWbVi00Vuu0tGsn3t+ON3pXpNn4c8L6REItNkCuFw9xKBIZD32j+H61pWWoQQXJtdEg2M0f764LF5On3VA6H3o5erC58t6hZXFhezWl5A8FzAxSSNxgqw6g1Vr2/wCKnw7kj8N/8JJAzG+Vi1zC7As8R/5afUHAI9Oe1eJMOTSsMbRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopQMmgBVVmICgkk4GBXt3w2tb3wdYzyXujSvc3qgyGWMgrH1Cqex7n/61YHwR0WzGvRa5rXlfZbJ90EUw+WaUHr/wHr9cV9Mf21omo7hBdRQ3DHeY3b5Xz/EB61aQmzzqZ/Dniy4iNvff2dqar5bI7iMyL3yfWtq38Ca7Lb/aNPl0vVLeMZiS4+f5fQMO9dRF4Y0jxXpbNqejWaXUb5F1b43NjplR61gDQNR8NXsZ0DU5dPY5YK8hMef7pBGBmnZknNJpPw81K6bSvG2h6hoWprkeeWJj69AfT0zU158AbaSP7R4L1i11K1cHEFwwB9uR1/Gu5vfFD27qPGeiFgyFGu4FDqxxwfY1ieH9T8HJef6HfXWkSu2C86OisTyMjoDQw1PHfGHwV8VaUn2r+ywYhwyw5fH1x2rmrf4feKJ0BtdKdyRwq8E/QHn8a+v5Z9fhjUad4ksr23kBBa4VWRfxH9a5qfQviGGeazk0aSNTlTu5YdfwocU1caZ8m6r4V8R6XcGO+0nULaVeuUOMfUVmRQ3ktw0Wy5nkPaPJNfYtpL49uo/KuNKgkhB2yOR5nHoM9RWssnie3tYxaeG9LhOMbzb/ADkZ9egpco7nx7B4ckcIb1JoVODtzkn8MV2Oh+AtK1LakFjrVxLkbnEW2NR7/wCNe7ajqPiXR5XFh4W06+u8bvNdAzEn0x0x6Vy2q+LPjBcSC1g09dKL9Ra2YJX8eaOQVyzpPwfgtrUTWlp9nKD5p538tAO+CeSfrVLVv+EC8Eosvia/udcvA37nTrd92SP7xB5H1rntU8M+P9V2T69f6teK5wRJNhV/4COB+VbXhPwWllfxrpXh43upLxJeXmTEG/2Tjmj0QepJoni7xb4ikceEfDlv4bsJTtE4hLOF9s8Zqt4ks5rKUSeJbu91aWN90fmZxLkenQc+1esWXhB5RPBqOr3c0zY+W3byhHnqox2q7J4RtrGxeKx2qQcvdyksU9gSDmqSYrnjWieCfFfi66R4bW20mxZcpuJXYh6sPU16voHgTR/DUEVvbrJLckYadW+aQ98D0+tar6rpltCFu3S4bAGAxQjHYVzeseP7awikksrXbKflQAbj+BPWi3VgdlJZ6XpcK3muG0ghRflRzuJGMYOev0r4l+Lnh6x0XxTdzaFE40S6cyWu4k+X6oT9ckexHXFe33Fzfay/228ulYSLzPO4wi54AX19hWH4h0a31jSrjTdgMYUubjGNrAfKQuc560nqNaHzlSVZ1C0lsbuS3uF2yxnBH8jVc8GsyhKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAra8JaI2va1DZGZLeFvmmncErGg6k4/Ie9ZEaNI6qgLMxwAO5r2HwhojWmmLFDZ/apmO+7mQbsDshHbHP500Js6GCyXTpltdOgje2iUeWobehQepHfvmtOC2+2RSvaxvmFS7DcQCp9CfSq1ncXNpGWs/LijUhFBQZz6kdx9K6DR9a8Q24ldLZJrp+DGsWMj1AFUIoWFpeWzWhsLy5g8xN5eRygjI7A101l488Q6Qn2XWra11axOOP+WhXHr3rc0TxnBdQrYeKNE85ZFxuVM5x2IPStNfCvhHVMrpsottwIMM4YAewz0/CmhbmdaeK/BmrWpW/juNNMhG5cl04+n+FQ6hoXgfVFbyb6IwsQfMckFj/v5/nWJqvwsmtZ5UjkMMLZKTbsoQenNczd+Brq2LA3MMsQILvC3yA/7ppgdne6HpsOlmytdQsXtJDlFLkMP+BA8j60ll4T1iG2QLrqTWud37u4Bx7Dr+ZrgoNDtICqxzLCSdrO0vyt68VGdFhjZnAVn+7m0kclh2ytFwsepP4S8UzyJNZeMprLb92N5AFHtx1/Kr1lo3iq2JjvfiFp8e4fdCqzfqa8dt/Dkusy7bc3sdsMq8vLOuOoBJ7VrH4c6SLho4HvHG0GWeZuf8j0ouB6uZotDRFvvH1t5xbL5iQ/ljpTk8faLCTFJrS3En/PSJDub69815tYeD/DNghkvNSmv0VfmhhQtu/wAK6nTLvQLB0g0fQ7SBQoLPcuEY+mQckmjVBY67T/E1lcLn7JJL3Cum0kepqe/8VWcUDW4kk0tzy0Sx7nI9RgVy1/4psltWkvb6xsY0OFFvH5jOfZj3rDvvE9pqECrpttNMWwpurgHgnrgcH8aYI2tU8VQiIw6THLcyv8pmuW2hR67R/Wue11hPABNr91eSgjzohKUjHtgcnFYKxY1TaLlXDHPBIH6dBW4mnQWcBMpgmugD5hWTGz23dyPzpNgYh09Z3WYvJsZQu6SQ4X1yD0FVVsLeeedEuDNcoxWNR90J61c1OWO1MJhnl2Ny5dCMgemep+tULzVYoSzfIC6khIsK/PHzep9h0pDC7Xy7c20ITC/NI2CccYAzjg+1ZOo38dhbNC7L50iBNsQDbPds1HdXdwPKRYWigjJJjZuXPqe5rl9QcfaIzAGeRiTjNIDC8W2U2oIszIpngyoIGC69ccVwzj5yBXrNxFaRx/NP/pOMlRya8+8Q2It5/OiyI5TyCMbT/wDXqWMxaKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApRQBk1ueEtCk1vU1hZWFspzK6joPQe5oA2PBGiLMn22eJ2cnbbqDgEg8nPr6V6dZf8JlbWhbRNHkis3yJJQpwSOo9jVNbWC0xbrIVEWF3JFyvpke1dz8P/ABHrbal/ZiX8C2pYZadflPoeelUtCWzB8JS6vPd239sW8UdpIxQMziM89s9ePSu70zTp9P1aaX7bcxz7SI7gMHXafWuo8QWo1eEQ3NvbPcIQQ1uoKN71jmBUuVR5HjdBhlwT8uOi/wCFWlYRaOjT2uoQXl5qH2iFgOV5YnsTiumu47RbZY2LyxOCTt6/keQa5aPUrzTYYmV5prc8RS+V82PQitK9+IQs7Ivf2lrJN5eUKg5Ye+aYilqMj6bZO1tdbgOsN0SFx6iuA1KZdXu/tjTpEqDa0ET549QD70668SQ65dzyXjNBCqPIyFDJsVVyTjucDpXH/vbtzPpNzp96SPLWFn8mTnOG2yY54xwfSsp1oxfK2JySdjqbVo1RZJWsbnawCs8gRh7YqaXxe0ZlhihgUocFInCqR9e5+ledX9nqGySa90uS32p1KMoPOAdw4/Wq0Vw8aRI0CFT1XGSPxNNTT1iNST2Z3cniK4+2Iyssbt8xCtjj3Pc+9aEutXOposcbGKyXLO7EfMfUnvXE6fc7A/mxjYDkFuD7AnsK1Evbu+V5Zra28vy8ZLjbjscVVyi1N4gktR5OniHpuLRjIc55zWej6pqV5LcfuoJh8wJY7cf5/CtPQrO+llh328b2yNt8yFQUUHsc1JPcW6SXL2dxEjg7ZIwdpYdxjuKQFO2ikuLxFln89tuSZioVfp/eFbNvFPc30Udyh2L8ykZKE+oPasNNU+wui3sccgUb0Rl+UD61Un1ye/kZEEzMeBHCzYz6BRnNFxXOv1S/tI4PICo9xj5vLP3OenHWsgalawOpinaNUQhkeLzGZj/d6c+9c9HpWqSAPBBJbQjGWuGEKLk4/jIP4VU1GS5sJ40muVmidNySwHchXJBwfYgg1PtIN8qYlKLdkze1HWVe3WBGuQxORubPOa529vDJebml8tgOCeST3JNQTblDF24ZfM3nkD04rLcxPgLtLY+8R/L0qizSl1DYAfn2lQuQcZFVZpWiQqm3bjOQR+tZt027BTgAdCaryTQouJXZ37YOATSAt+YMliuc9T3rPu9k4ZJD5gfjcf4RUctw8h+6UU9Md6kiVJUxuGR0AHNIDk7uD7PO8edwB4YdCKgrr9W08XluFjQ/aV+4oHb0rk3jZXKspDLwQRgigYyiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFLg4JxwOtAFrTrOa+vYLa0QyXEzhI0HcmvaNA8PjSbe3sbaVY7hiRI0i5R37sGHp0+grC+GWkjTrOXVJG8rUGG2JGyrRL3bn1/lXtnh/RJnFvIyQMWAO4fMuT39s1SRLZzfh3QkS5uI9amdYvuNNEcrntg1dj8Iw7/M0tz9oP+rlLE7iPb1r2Cz8GWs1usgMcNwoxLFtwr/X/ABrgfFejjSZZXs7hkVQHjUOcK3+z/hVpaAanheY6NCHlmInUFZomGQf8DVtNRjuUa5u9xVs7I1GdynpmvI7+/wDEF3I11J5U8IXG4A5IPHze9T/2veDS3kR5pNnytGMjC+u7vRcR3fjHxFNYR2drY+QwALZZtxA9D3rzfW9TN9HdpO08lyMeXIjjYAfTPasoXQvGUJJIZuTw/I+pNadnbaaumFrqa6jvJCcAKNv1z2ovcZSe8itdBklZ2eadls8kEcfebH5KP/11zhmt/MEBJSPOeRk/nV3xIywizs0m3JDCLiXHHzyfNk/8B2c+lc/HLHKhZojMx4UJ1rCm9G31FTje50cGrGwbba3UsLBSoNvMV4znkdPwpV8XXJ3fbjb3asBHm5hSQsB0y2A2R65rmWmvyJbaG0aJDy+6Pnj3NS6NbTQFpEhd26uJE3KvvTlThLdag4xe6Ot0/wATMzNCNC02YSHaGWMqV+hDc1bvtcuGR7N9Lt/JUgKkcjglvzrCS1nucyw7cK29gh2gf59KtTOxtjJIJkuVIYBQAu3uc+tCpRW2no2vyF7Nf1c6OzvIINPY2+mxyTo3zmaeXC/+PZzTLrVNPhnjWTT9N+0yJgKPMB/E5rlTLHI0kkMzg4CBVYjdn/Ct7QFsIX+16rbtqTQnPlhsIij1zzxR7NW6/e/8xOnH+m/8yWC5ubi92Wml2azP08uz3lc8dyRnnqc1f1d9X0krDd3MtrtBAhhYRLg98IAM+ta938RbOzQ2+g2BimwCsjn5R+ma5i4vor6WbUNca4kQnH7kZ5+hNP2FNboFBdjBv9QjlLJ5aO5A3yOcnjpzWlpiSaloEBgt0b7HI8b5xnY/zL9BuDfUtTdOg0nWL/ZEbyUAjYGCjBz0IFe3eHfhy9hpMjSPBdGZBwvyBCOVz+dTNWSaWwS0s0fOVza3DTPHFAYjjPXPP41gXcs0UzQzJhwcEg9R9a9W8d6Cuk60I/tkLTAbTArZYDrn6VzV3oRvrI3LZXnqVzx3PHatWrGhwTMzNujJXsec1Efmfa7fN3PStPW9EudPZJY5NykZyO4qkL3Fnlo0aTv8vSkBCxywIB29MmrFrJtBCKS/TzPT6VQSR5ycA7QM7F71YtYm8wiXAyOFBxikBrW0EiRNNudY+ox95vU59Kx/E1gGRNRhB2v/AK1vU/3vxroYfKZTDIwwgHQ/zNSu4ZylxJvgb5fLU4Ug9qAPM6StDWrE2F48YGYyco3qKoUhiUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKBmux+GelafeeIbe416KSXR4G3TRxnBlPZPp0J9q5rSbCbUr+O1tx87dWIOFHdj7CvZPCkEen3EWnWyxmJVIVpOC7Y5/OmJnW+IrTRdXvxLa38lq+0KsrRnEi9g2OPbNdBYXWtR6LFbyW48+IYiuUO0kDpjHBFcrp9hMl5JbJJJbtjOVG5QD6j0rttLvr/AEy0WIxQ3ZRc4AG04789Ktbks6nSfHm7TUh16xeK6jXatxECyuPXpj8K5HxlONStheadeR3FqGG4A/OnPJIPpWnH44sfsmIbNbdyf3sUxyp9cU3xDqPhHWNKBBTTNViHySRDh/Y46iq8gMCwkkubJntIEltwNs5DH5fcexrKa406zu2MuniVTjeschIc+/vS+FZ5hdy2cTndLwPKyD/+qq+vaDNYQyyieW4u1ky4U5OPWpWw0T2i+FpzNJb6Ff2l2TlNjkgH6elc1rdnNqeqW0TzYinlUSKh27VB53Y6cZ5roRpscMNte6nd3QL5Mexihz6E1yut65GLfWrmJnzFb/ZUZXxmSTKg59dokP4Ed6ibtFky0RUutG1TULbUtZFuZLKSVyJkII68AgdOMUvwcvtO0XVbu6vLR7iaFC0SvjCnvwe9YHg+8ljj+zF3SOU/MBnaw9xWpf2oic+QztOTzGgzx6g/0rehyKm4Sjd9H28xxutnYt+LPEt3r2om4kjEFs77SqAcf41Ytks7cM0d1MYyACWQBvoB6VkWbTyABYwzKCSzNt/IetaMKR7WjkZ0Zhl0Ygk/SsnqUQ3V15U48nbED/GRtDD3qCa8u5DvuC4hwTuxhc9sVBdtE6Sj7Q0io3yRycmopt+23mdD5J+UKWyMeuKQE8NxM375Y0lh6JtAHPqRV22nuJuZbVN5PPJTcPQiprGwjubkRpLHZo2CZEy36e9dHDo+mW0sEssz30YJEqRE7gPZR1NNCOWvW/eNFMr2kWNwIGcD0rJutRxCymY/Z1OSOAWruPEx0+V2Gj2zbEUAieTe/wCX+NeZapayzTSzSx7ApwMAAD8K6cJTp1K8YVnaLau+wm2loep/Be+tLcXOo3jWccERxF9ofLZHXgcj611N1461hNaa5hNpbaWDukMMpZXGfX1xXn/ww8Lahq7l9IsTcBMFpGiyg9jnAP0r1RvAus6rCw1iSN4MkLb2irHkjpnPAp42lShWnTou8ehEdY6nKLBZzaxqEV/Y/bLy4LCKQlmZR1BP1BBrC/s6HQdUmWa5muJdmcQsCsRPqTxXsuiaFYaVpz3eq3kVpdRJsZI3Us+wYxvPqMZ968F8S+II9X1m+aFIordXILNJkEf1NcdNtwuyoO6uaOsWEGoWGVjjPy7g47exx3ry3VbdrbUdkfIH8J9a900O3mHhNruCKBIgOCp5PuB3rzH4g6a9pIs7RpHkA5B+b8au10Wnc5wErneMBugQdahGXuE4f0AHBqK3lZbdg/zN2z0rStYH2Dy4JHmJxuxmoGSyeXHIVVQxGMhTnP1qYMXA8whMDK8VHLYeRsM6hCTyM8mnGREIjjI8voc8lqBDL+0jv7GVJY/n27o5ByQw/wAa4SVGjcq4wwOCK7+T/VEbtoPQjrWD4jto5k+1QoQUG2Qt/F7ge1Azm6WvT/hl8FPFXjwx3MVv/Zujseb67UqGH/TNer/y969x8f8Awf8AC/w++CHieewtvtmrfZ0DahdANJ/rUzsHRB9Ofc0gPj6iiigAooooAKKKKACiiigAooooAKcq7ulIK7T4faJa3cz32piUW8X+oC9Hk9/YfzoA9N8K/DfUfDPhca1LKkd/NGDcQsmfJjPIXPfPBP5dqiGnyC9trnT5EeQnzMx8lcHnFdX4S+IK+HyNPvN9zp0gw4lO4DPcf4VneME06XVTdaFF9mEw3p5T5jYn0HY/StNGiTV1WdZ5bfVNKmkS8C7JV256d8DrVOPWdaF+JZLi0liYblkCgY+oNZHh7VJoLhIVCoznawkXIz2YEc5q549mu9Nsliu/s7tL911HzAH1Peha7gUtd1i31C9Z53QO5xmBcZ+oqpZ6DPrExT7Z5MhBx5mAHI7D0rmrS5zKNyDnlTuxWleNIltHcC9SUk4KrJhl+opXCxdgl1PQdShWFDa3cB+SXfnf7elbGu65d+Ir4XV5dfZJkUZ24AY+/OK5OTV7a+g8u4SVLiPpIWyD+FUIJW8xiJ0TIwQ6/eovoB1Xipr9bKGO9uZnRhmJQfkI9RWdpPhS+1WxsbC0jDNcl7yaZuV2/cQE+wDcerH1rNvNU820isEWWVw4SJVcnknAAHfrXu3gzUNDTSFh0uaO4EH7h2Q8kp8ufocEj2NceOhi6sVTwUOafysvN3Jlj8JgGq2NdoLybu/kcdYfDTTraCKCWa8lnJ/eOJNqj6D2rj9U0p9C12+sL2ZpjDtZHBwZIz0PtXuVzrenx3MagAyE45OcV5F8Ur+21HxUXs3imCRqskvYkdifaoy/B5thIuWZL3ZbdeX1eyXTre/kT/bWXZrW5MvTXKm22rKV7Kyvrf5K2vc5y7lht5TNZYCOOQ77iaicyRyiaUJ5MozhF/yarxneHaaKJkBwHHBzTLl2R4pPMYjurN0rvNR05s4CQY1lEgJ+Q4IPvmptK07zdkkrSEZ4Reo9yfao7adZLvYLSFkY8NMc7fXBruHu7W1SK30qNFbytzzMwkHvgdqS1EUbG3txerG0qLbMNhVicZ9SRVu8uP7IvJRIJtNfaAj2qFxIPr2z61Wa+niWaODyoGOGT9zxIaqw61mKS31QsVc8ooCnPrVASy3NpY2kklsDLdTjEhkUkn8TxXGa1OodYYZQ7sNx2AhU9uetdhcyadc6XMsdjeRXKjbCIej++a41tMvPLuJZbW5kmVhhYo8hVwclu+a97IKGDniFLFyWmyfV+fkY15TUfcRr+GvG+q6FbS2SavPFbSKRsXt9PSl/4WF4n2PDDq86wkkblOSa424hknk3LE6gD0qVZnt2Qv8Au1A4yOfrXscQ0suhSlKjb2l1t/kY4dVL3k3Y7e3uJrzwvevdTTCWCdJjIz7iVf5COenO39a5u2097GR2dFkibkMSGxWn4SlNzeSW883yX8TWoJXgM33Tn/eC59s1ThglnmSOQhAoywJ2kD6V8HDRuJ1R0bRv+DtTvl1eGHSbcCAnayS87j9OgrovjGsK6RYjCrdSAiTadwB9Kn8FrZmVTAiRSRpjazEbz61j+P8AUrXVZobXzDH5XBZhgH/69ax0uUtzg9M03zIdsqK65yZCOBW3prXEStDAFUt/Hj5iPb0p8VpDCiRW8bfN1knYZP0HatX+z4bOxO6aOESDLyyDH4CkMztQ0xLaJZJCpnbkDOSM1k3NqtsoJgYlzje/AH410GlRXOtahHp3hbSZtUvO7KmUj9yTwB7mvbPA3wJQul/4+uhf3GQy2ELEQx+zN1b8MD60NgeEeEPA/iDxfdmDQtPEsSNhrp/khi+rdz7DJr6T+HvwQ0Lw6sN1re3WdUTDBpU/cRt/sp3+rZ/CvVLGztrC0itbGCK3tohtSKJAqqPYCp6kYiKEUKoCqBgADAArg/jvpd9rXwl8RafpNrLd308KLFDEMs5EiE4H0BrvaKAPzq/4VF8QP+hT1X/v1/8AXo/4VF8QP+hT1X/v1/8AXr9FaKAPzq/4VD8QP+hT1X/v1/8AXpR8IfiAT/yKWqf9+x/jX6KUUAflxqNlc6bf3FlfwvBd27mKWJxhkYHBBorpvi//AMlT8Wf9hOf/ANDNFAHIUUUUAFFFOVSxAUEknAA70AXNHsnvr1YRkJ952HO1fWvXLK+trKCGO3tglsihTA3IA9c+vvXKaHYLZ2COpAnPLkDr/s/QVrsdqCReAewOQfamBuNarezbbDaPMGVRjw3sD61CunX1qg8+2khjB/1nJGf8+lTWiSWdn5yMZLST7y94zXSaJcu0SQXFyZrQ9Ruydp9RTJLml29vqumldTliVAvyXUeNwPYkdRXD6/BdNLNbzXq3qRPhHU9B9K3/ABJG+iKf7MuzJbSH5o2IKkex7H2rL066aCdLmO3EsI+8DyR9R/Wq20A5iCOSO5Uj5XXpxxU1/cNdXDNPEgcYB28D8q37u1tryeSWCNkUjc4botchcKv2h1EgVkOB1waQzRNvb3MIIZo5gOhOA30NZ8ahZthyG/iU9KRJz8u5icdun5U0usZDKWBJyNx5pAb/AIe00rfyXaBZFtIHnXackOOE9/vEHI6EA1o6Bc3vhVkuzYTi2mUJISSFbPTkcZqv4VaSXTgsZxc6hOAq/wB6OPqfxZgPfaw7U/xw97pkUenrPcRQOpaS2OcMSc5PY8/TFelkNJV8b7z93W++3yOHGU41qcoyV+gzxT4tl1nVI7XT4hZw4AOzln+pptxp81laK9zbxmGQ4Yrncv19qwNItZDqkdy5yDwOQMV1WoXDSRi2jJicDkZO1h9c1OY4l168uV+6tF6FYLCwwtFU4K3fzfmZyQR2sEr7YHO3IYN2qPSdGnvJdKvLq8sUh1JZTbbn/hjfY24Y656VoNfW+h2wmtmWa/jw6mSMPGD7g5BHsawrnxbNaaVZXunRRx6rqn2ldVmawQJneAiwErtXCEE7MYLc9q8itKpFx5F+Pk/LT8e3W67Ujo20oWmqyxtFaOyjg84+ozVrSoI2vSGtxsC/METlv1qtpVzbSra3F4w811GxmO4A++4107raXVs14ZVtZc7WMIGJD2rp3ZIttqNtYyJFBYW9xNEchLgHemfT1qxdX66i5lmt7OwcjlzBh2/2RwcVm2TzLJJcLJZLJ0EkrbpF9Mdqlm1OVJBC9wxd05AUfMf6ZoAs6RpNm0BuLi+S3bJYR7Scc9QBxWJrGqfZfNtbG6knWZsuQojyPciqmqX7CcRtaujj7qRsWwPc1UaYpc+ZCwgkz0kUtn8cUAjMngt4rnzZRJtBxsB6+9ch4vvZZ7tecRL0Ht711viG4eW4HllCxHJ5AzXI6zBGYSVJDd2x1ou2M2fBNynnJJMQscWH+UAnI5+UGtbxXGtvrV49pLOVucToWw21XG7G7v1xx6VxXh2Y2021Hw56c/rXa6vbTSaNpmo3DK5iV7Zuc5Cnchx0+6xH/ASa572kmQ9JJk3g/wAQz6ZeRmNonZvlO4E5Jrtvixp9tY6Np12oEVxNl5CU4Jx2rzrwRHBd67BLcytFBG4b7uT17V2P7QGtpeizgib9zFGMbmyxreG7K6nDDVREiyWKmaRP4pOQDW/4evtIvNRgl8aS3klkT+9W0I3j8+3059K8/wBGfzTgHb7V0C275UpEc/3nIyPoKm4z7e+Hi+FV8PRDwQLIab6W3XP+3n5t3+9zXUV8KeHNd1Hw5qgu9KvJLWZVxuiI+b2YdCPY1714D+PFhe+VaeLIxZz9PtsSnySf9odVPvyPpSsM9xoqG0uoLy2juLSaOeCQbkkjYMrD1BHWpqACiiigAooooAKKKKAPze+L/wDyVPxZ/wBhOf8A9DNFHxf/AOSp+LP+wlP/AOhmigDkKKKKAFFdP4RtEjf7ZcrnjEQPb3P8qw9OtGuZsY/dry5/pXU24MeDEwCjopoA3/JLH9yuA3LKpyKsxw7cCOVX28MjjBH1rJguZISJINwZOoAzXd6bNp2v6cjsIrfVrfrxjzV/xqhHPQNMXdULQxk/MoPH61uQafLp9sZ7e5DDGSqNzj29a0fsywWv2iWKNoz0wMZrjNZ1IpNJHbE+U3G09KdgF1K8+0Ex8uB3b1+tVtOu7iwlLrlVzgBjn/IrOtJZEZgcsrenI/KrUdwjZ81WKjoQOVP070gNa612WGJ45baNkmGMjgj6Guf8iSUtKpyfQtzTrmTMoCyKUPQehpgnIbYBlT1NACBVcMGRhKoyCSaptvUcty3arxkHJb5SOhHarOhpHdaxCs4DwxEzyD1RFLkDPGSFx+NTJ8qbE3ZXNqNPsmr21kZtq6fEsTBW2nefnc+3zMfam+Pb61vbi1exd5Zgnzu0hZs/3fpWNLdyXMczswFzPIXb0yxzgZqjp1lJHfMswLY617WU4ZUqE8ZN/DdW7tmLauodTY8OxBJA829AeWTGP/r1r6vOuSIR5Y4Chj/Wo0ufsq4mbzYgAVU84/4FVDU5SUea3TKPzsfnP0xXkPfQ3MPxHdvOwSLG0fKew/SsS6RI4YDHcmWUlv3PP7v7vPp83tz8vParl3DcTuD9nkjGeQqEg1e1DRLS30LSbhJRLc3CzvMsW4vBtcKqyD+HgEjpwfpWU5xjKMW9/wDJspK4nh6/WeYW14XwRjggfzrvbXRp7FFjtY3l4DMc7uD3+lcvpmiWd3pMctu3+kDo+eMjsa67SfF1hoVkTc71vWXYVUkn64qMHVWKqOlTTcu3U9HMMpr4GnCvUs4yWjR0mnaFPPE8lnbpKAuZMkgg+xHFUJHs7S4U3FuhkTI8uVs5PsQaydI1R/EN9cyWFzcxxx43R52ZB7nH0p2swafZKGsY5m1JfvGRg0P/AHzjNZ1sdChXlhqialHvp+B14bhzE4qjCtRafN0Wv39F/SN2/eN7RYoQLaWT5h82Cv5daonSJGCqzXUsjDDSlgqL9c9a5vTfEV8zJDNNYNqDbtkUhWJIkH+0cDJ7Aelb/wDZVxqZUy3toxGC6RXH+GQa9GVJxgqnR7HhVKcqU3TmrNOxX8RaLaaVYq0V0J7liDsUZOPc5rz3xDFNLBLNGuIh1Ceteow6RoVtHLJML2aUnA3EBQfTJ5P4VwviyzNsrosZAPzAA4wPcetZ2EjhNIdFvQ78KMfKR3r0i236j4c1S2WUtIqLdRDHQocEf98sfoK8+SLypN+N7nrxwK67whqlnbanarOs5ikbyZj/AAlH+VifYA5x7VjUWnpqTPa5L4adLKQTTDIjwx9Ca5nxrrU+u6s00jd8KgPQf4Vd8STSw3Fxby232YxsYzHuyVIJBz75FceWAmYZyeu6rT931KWup0OkbbWZHdS+OoU11VxqCTxrsjjt4+jCP7zfjXBwTowA3Pn61pW8ytjl2YfkKQHTy6jAtuIYLYIp6sOS31NZ091JINqLsj/ujqaopNN5mSwOaSWcvnbkAcZFMDrPBXjrxD4LvPN0S9ZImO6W0mO+GT/gPY+4wa+lfhv8c/D/AIpMVnq+NF1ZjtEc7fuZT/sP0/A4P1r47Yrt3AsN3HJ5p4tGaMGQbYz+JI+lFgP0dBBAIOQe9cR8a9UvtF+F2v6hpV09pewRIYpk+8hMijj8Ca+YPAHxg8Q+CRFaRu2qaWmB9kunJKj/AGH5K/Tke1euePPid4c8c/BrxFHp919l1EwIWsbnCyg+YnQdHHuM0hnhjfFPx1tIXxVqPT1XI/SsK7+LnxFt5SjeLNS9jleR+VZE8MpcAscnuR0qLUrBZrMAf65fuk9/aiyA1v8AhcnxD/6GzUv++l/woHxk+IYP/I2al+a/4VwDAhiD1FJSsgLOpX11qeoXN9fzPPd3Ehlllfq7E5JNFVqKYBT4kaSRVQZYngU2tXTYBGnmuSGb7pHYUAa2nwi2gESkZ6k45zVkKU5A6c47GoI45MBg4b+tSqhJDAlT3BpiL8MheMNGo+oHI9quWRCAszbT1BU9D9KzFj8sGWMEg8EDqK0badWjCzqMno3rQBpnVJvsjKLksh52njn/ABrmL+XMu5mLNnpirl0VBPHXuKoB+cIMgnqabYEsZ+UEcNUrTtGgYsDn+H1qAthSG59R6VDuDY8zgj3pAWNwkOSSpzTwV3HKk/7Wearo/wAu0EK3tzTtrKwLOo9cUAOeVOWJ/AGtrQUd9F1O4UBWnKWaA8ZB+d8fgqg/UVhgRGQbwzA9RivQlDaZp+lwRRlAIjcSZTgmTBAOO+0Lz74qKmtokT1sjj55IvKMEaBJBxuYZ5pLSNpHJmkQMR94nAFdPqUsOqQl57FItnHmRj5vx9RXPxWkcNwzCYScdMZI/CupV6kabpJ6MfKr8xPHb3QdGglVkzjAb5TUU19JYzgiT5wfu44/Co5WSHd5bSOW5+U4H5VjXN9JuUkMxU5IJrCWiNaajKSU3Zdz1jw58SFSykintLnzWOUmREDKQMAhuCD71RAu9eubHTtJ1G60q4vzLDfTSXMjJeNLIAu8DJPy4U9M1z1gIbm3SaFjgjnHY1vaLdLpmo2d8qCRreVZQhOAxUg4/SvncVjpuS0s1/w3zP0uhwlg/q7qRbm2tNdL20OTt55NDE9lcDckcjIHVcA4YgkexxUOoxrqQSW3bY+RnzE610/kRX908U6q7O7SlecAkk/XHNUNQsraUbo5BBNGcFXYBfovevTy9yU/rdBuNRPf+keRmmOeCUcsxKU6dlddU7bXQeGIDpLtItxl5cBieBXr+neHLO70Qy3V1ZSW7je5RlaQepz1r551y31G3k+83l/wnPH51Qt9dvrK4xDM8RI52sefrWvsJVa88Tinzzlu2eVmOdxqUaeHwMXSjDs9X+vmfS+keE/AcE4dNBl1OYYLO7tj688GvQbDw5oiyA6do8QRk5VOWH+FeI/CT4gXzMba8uPOgIx8hVXB9OnSvarWLUdWtUbTrqaKM8fJMMAe+BzXdGd1boj5yUnKTlLVnOeM7Oy0g+ZaaRCJnOOW+7749a8s8V2lilkZEytyfmZJo9pP+7XuP/COxpfJPeXkaSH5dwHLfia53xtY2FrFJ513LJC4xkqrhfx7U7CR8n6nLuvCN4UZ5wa6vwVLEZtr+Ts7F22ik8U6ZYrcvJp6vPk9Cp5rJ02C8hnRliMY/vAYrOS6FPU3viXap9vW5jWP/S4knO1cDONrY79V7159NbbCWyQO3SvT7q3lvPDsLXZCGznZG3HkpINw+p3K/wBOPWuE11YouIihU9h1rOGsfQmGqsYUY3MRt5Hf1q3bnaMEcHvngVVRgHJAO70BqxboznoSfeqLLm4vEFVzntjvVpIpguBwccjHQUunRBBvZQW7E9q3bWxiliBYytI/J2j+VMRlwRpDERMPdQBkn8KeLaSRN7Bo0POGrqrSz+zxkJBHEoHLP8zGqz26vmW7lEcOflyfvfh3p2AwEgklBjtlw306/jU0emyKrFyo28lh2P1rWa+tYspY25mYdSeF/wDr1Q1S5keJRO2GPIT/AOsOlAGRcGIEohYkHk9qrh23bsj0BPakuHLSbQvC9cDrSPJ93CgKB+dIDJ1e2UOZ0HU/MP61l105Xdkuu5ccj2rn7qAwSY/hPK+4pDIKKKKALun23nSZcHyx+p9K2oYA2QSQRxUKwG3RRFggevepUz1bt3NAEyDaNrHoelTqwPIIYVXxkBxlsds9RViFFdWKKd/oetMRIjBkwjMD/dPWnvO6r843KOOeoqoj7WKyDPPBzgil3kk7uo6H1/xoAt7lkUEsB6VD5aeZ/rNueoI4qu7gocKR9O1RKx/5aAgUAbf9lzyW5kQmUHuBVNrE5Py4boQetWNG1W5siy2zjB6owyK37fXLK5AXULQRyjoyDaDQByv2QqvKjP8AKoir5JAyenHeu++y2zxlreRUjcZORmqR0pBKBtjyf4k4/SnYDO8OaPLfXdrEVkxJIql9uQqnqT7AZrs/FTXkgku1t3S3duFZMEqOFPHfAFdR8MNPRXdpCUZBtU7eCW4H/s1bPxG0K5tdJaRdgjUbjHkqpHqB2P0qILmm320/r8jNaybPE0uTK6rJONi8gsSGHtWp9njmgM5jy+Mh1way0iE3mZkjVhyo284+tJvRAITL5Z6hmXAqzQz7yWSWZzEAATjLcVQm08TTALKiyZ5OeBW86LhxNEsgHImjbj8axtyvOyGMFPQj+tDA7nwb4C1jW0Is9U06KSPpGZh89Xtc8Ka5ocyxXzaert0InzmvNJk+zTLJbTzoeo2t0/Grvh3VmGrLJqEs92in/VyOf61z1MNSq6zjc9PBZzjcDB06FSyfT/hzuNPstQNw/wBluLfzAvMhTaB7ZI/lWFqqXNpfZuhbOx52lt1dNcahDdwn7PdtHEw4ideB7A+tcnqWj30y+fGJZIieHbGRW8IKEeWOxw1q1SvN1KrvJ9Strs7S2ib5VcYwADgKPauNeMGchDlj3POK3tZ1AR2iwSMTt4IeMdfrWPZ6ssbg7ExjrgU29DO7sa2ghllG0bc8HHBr2HwXd67HLGun3EkiJz9nfKq31zXjUGqOw3QwfN1yODWhba9ffaNqXs8Tjnbv/rSTJZ9Nbtcu7QXWtX1nZjOFt0jG4D6mtWw1XQrK2C6pvvlx90R7l/EdK+e7TxCwWNtQ1q4cjpFgyMPpniuk0T4naTp0LLeaVfaxKThPNnEaL9VFXcVjq/H/AI/0QafJZ+HdChSQgiRzEAVHtivnjVNdm8+SIMsMZbftQkkmuu8e+J31uTzbXRrXToF/ggY4/E968quJWN2zE5Oe1En0RSOu0G/n1JtTsPMkH2uzcRlj1kQiRRntyn49K4+dtxLk7j/e71oaPqL2GsWN+d2LaZJDjk7QecD1xmk8R2RsNZvrRAvlJK3lkHcGQnKkHuCCDnvWK0kJaS9TLibIHHOevtWrDcmKNUj3jPXFZSgZBAxV6wIZg7AED8aoo63RbmOOILJEhUcsXHWum+3u8CeTGkSdljGCa4M3RLJydvpitGO9bgLI2cYwKYjqo51mlCXD+VH3Gc1V1U2003yxuY14Un5R/wDXrAM0qtvMygkdKsLdidh5jh8D1pgFzdMuY4AkadeByTWRh2mZurdSavTTRks2Rs/2hgGsxpMk7yxUngDgUARuxV22kZ7nFMdSRgsefSiQ7e2Meg61Gzgr0bHueaQx/HBYkAD1qPUBHcWwhiiChfmMh4JNBG4ZJOB69KY/mOmNvHoOp+tAGDIpRiCMEUVoahASA4Ubu4HeikBoFyX9RmpxKuNq4J9KrTFd/Q/hSRlVORnJ702BaQlOg478VPDc+WcNjHbNVBI3mAg4Pp61M5XcMEZx0pASz4l+aMgevvVZm3Moxj2p6sAOR+VRyEMQe4pgPZ/LJHOD3pQ567QR3BpVRMA7sr+dRyKF4Vjz6igAkyj7ojg+lXYZzKAGQgDrVNdyrh+vZqeC8ZDoxDeh6UCNa1u3gYMmXX+7mta31om5jmMSSqnBUjkVzMcuWJkQrn0PFT2ytLdxx2rukrkKuD1YnAo2A+mvhpqWmTWVsglFpcXGZBFL/GASoIz7hv51ofFO4eTSmt5LeQxgZBBBU/SvHtP102GvPahI5obYLbKr8A7AFJX0yQTXruiS2viKzVVm8l1G1oXb+p60sO7LXqZQ0VzwaSzkgulnR0RCM4HIB9Kp6hfwPIG+UkcNkZAr0Lxl4dl0u6mDwyujH5ZBnH6V5nqEEcZkCBR7jn860aNSs90C7siKEf8AuDA/CobYxTSZdFIU4z0qlPLKImUnaw6Acir+hABiLgJtxkp1FSBefT47kMiKFXHVWBrCurCC3uMreBsdQ9dTZ6bbXVwUimKZ+78xFc54vs3sZCMK2O685oAlTVpYrcJFOhUHPIq6dXmnjEkczRgdV3HBriVuvMj2N8uOxqb7RIYSilx7Z4pXsBPrFzNezOJcDnqO9ZixjO1Dyeo9amZ2GQT9cdaYMttVCM/Shu4y1bSOmRnOPSr0Ug/1isFb171lbv3nzEgjuo5qzFGuQy5OO/SkBsw+bsMsUqqueV3YpHnLK3mj5h1IHWqsUpKAHceeMCrBTjzBuaTHRhTEWGuZprbY5Aj7AYFctqAEcxyoGf1roGuDFjcu7jgHHFYF4BJMzsCBnpmh7DK8bA8DAHoa6LxN/pWn6Lqa/N51oLeQj/nrD8n0HyeXj2571zoGDwPwrobU/bfB1/bgZmsJ0u0BPIjcbJMf8C8sk/SoelmTLRpmAHI7cU+B9mcZA74pvsevpSDJ4z+lUUXkmD8En6AdatxXAXAZmBPAC1lJlTwTircLEHJA6flQBo70IOxGIPvTRIygpGWA/ix0/Oord2HU8HrirAjG3IYnPrTECOB/rMFu2TSsc9SSBSKhkOFXp1Pc1K0EeArOB3wDQBVkUOw42+560hRlQttxGB1PepmTcxKjCjoScCmSMc88qPX+lAytklcnPHU+lA+VflJOe9Kx2htv15qEkyFU3HJPpQAM/wA3HPbgcmitizt7e1G6ZfMnI+Vc9KKQGSz49MdD6inx9eMMKWPbgqy89zUq4HDD6ZoAetuJMPGcexokhUPjjdjvTVkaPmHKn0bpTZGMp3AgMO1MBhYgnCtjvilEhBznPsRTTuH1phbggnB+lAExdH5ClT3Hak3hgORiq5OBweR+FP8AMwMdQfSgCYuWOD90daUFRhc5x+dQA4Oc8e1TAqvJBx70gJAPmzhSPWtrwx8mqfbGAK2EbXRDDqV4Qfi5UeuMkdKwGkUIQNuevWtq0ItvC8zsf3uozrGAe8cQyTj/AHmAz9fWpqbW7kT2t3F0u6ntmWVf3+Dkhure5NeveCPGnhpJYxqv9padcsApeMCRD+B5rxizWORgJJlHfbjNdNo2n/aJBFGWljY4ICFtvv7VY+W+x9DtqegajA4ttZt7xMf8tAY2H1U4rwrx1p8dpqc8kBE8THIaIZA9q6H+wbyztcPIPIHUEHj6HFZeoh7OHbFLmJuxOR/KrvdAeb3UqORuJXtwMH8al0iR0lJVHfsQehqXxJbLceVLGQrd8cVZ0R4FjRbuOUAHGUbg1LGdVo9m126sg+fH+rA5P4iqviTSPMglEw8pl4ClcYq7oOoafaaov2eKaQHjZnv+FafiD7Zd+dM6mG26gSHJ/KmhI8M1azazlwCDk8GqccpwQwBNdL4siVXyuSOxwK5mMHeOPzqWUWYyAvzZPv6U4Y2jBOR68Uxk7cD6UgyOnX86QD956k4P0qVWXBG7J/2aiIyuTjb78U5CvOANx9KALUDYZeSPXmrc8oc7U3k46k8VmxOF4BYH25qRnYjIdePWgCa3kQFlkAC+pNVb/lgIiCvfFIJOfm6eg6UyTYw+XIPt0NAECjDdwPQ10HgxhLrR0+Q/u9Shex9RucfISO+HCH64rCIJ46U+2ne2uYJoWKyROrqytggg5GD2pPawntYY6sjMrjDgkEehFAwenHpW54xhSPxBcTW4Vbe7xeQKowAko3gY7YyR+FYw2g4PX1oTurgndAmc5wDjrzUyuRtx19qhXOTtGfrUqts46k9O9MZctZBvG5SVBrQchlLE7Ix+tZ0anaMqQevTirEbSFcN1/u5pgWPPAiwmc98U2LOW2qQ3qRk0zkLkEHBqUPlSCSqd80CEZkRMA4PXrkmqzHy25IJPrU7hWGE2geuMmowi8rjJoGQkE5/un86YQIzlOSOambailRjce1R7GfKgjcevpQwJ7JJbmdY4yWduMjvRXeeBPD8e9LmZ9rfwIF+Zz/QUUrEnnUQVhg/Kae6jG3fwOhNRFuSMZI70M5+XjNMosAhQRz0pE+fGAEYdxyDUDnnKjt60iu2wkFh9aAJ2Up95s+1QnhiN3X1FN3M/D5I9RQoz/8AX4oAGBIywXHqKOgwoGPWg8feA2+lIwyQV5HtSARiUGSAQfWrKKXi+U++DUJG5SpAx6VGhKAru4PpmgC3CqhPnZd47EYrqtCNvqGn29lf6e1wluzlJrefZIqsckbSCp5HU8/kK5KymaJ8TrHLGT0f/Gu30O30Bh5klxe6XP0EkY82P8R1pSipaMmUVLc6HQtD0aK8LQKlxHn/AFd/G0bAf76ZA+vtXotl4b0K+tSlnHfabegH97ZTieMn/gJ/HmvI763uEnWTTdVtbtRzuico/wCRp9prt9ZMDKkgm6LKnBqfZyWz+9X/AMv1FHng7xZ2UsPiHTLmWO21WS4ELf6s8M359fpWZqniW5u5FttT04M2PvPBtJ/IVFZ+OdW3or6jMEyPluIldPzIJrs7HxRBrQJvYtMlkUgFifLBHfpT5px6fj/X5hKc2+Zo8d16KFt7GP7K69Fzn8jWbBHOq7UZZoyOTjmvWPF9v4XvS4vriS0duUaIrMhHp2xXGW3h3SRdyNY6/uiwSnn2rqB6BipOPTjNVKp3T+7/ACuLm8mUNIM1rOHWHbg5+fAFdxq97BqGkJ5nl+Yq9cnK/rWRpOiz3VuyQ3dldSg4EaysmB/wMAUn/COantbzhZkYJEa3cYY/njNL2kV1BTRxGs24ckCRHHfbjIrkZbcCVlG8t/ebivXI/DbecFawRQe/2iI/+z1s6l8LoNc0gyWSLHdoM7RKpyfwNHtYP7S+9D9pDujwdtyYyMj8DUkLRM/z5A9jW3feBfEFncyRNZABTjm4iX+bVGng/XdoP2JfqLqH/wCLqfaQ7r70HtId0ZbBSx2AqO2TTAVwc4H0rfTwjrUjESwQQRqpZpZruFUUAcknfTV8NyrzJquiKg6t9uU4H0Ayfwo9pHuPni9mYZLYGTx2o6HIJFbo0fTYgWn8SaeU7C3hllf8io4/GkNt4chwsuo6pck87re0RFHt87g/jjFPm8n9zDnRgk7uGz7GmvjPzEgjpXQrf+H4UYR6BcTyEj5rvUGIUewjRDn6k9KdF4tvbYD+zrHSLJwwYPDYoWyOnzPk8UuaXRBdvZGZp2janqn/ACDtPu7nAJLRRMwAHXJ6CtEeG5bfnV9Q07TgOscs4kl9x5ce4gj+6201Q1HWtW1NCL/Ubu5VhhlaU7T7FRxVDZtU/wAHsRTvN7haT3Zt+Jbiwmg0q3s7iS5ks7doJZ2i2K4Dll2gnccBsc46DisRcjpwPSlQZOAc9uOlTiHALNjimlbQaVlYjypVcDb706N9jDygM92zzSAMcKEYZ9s1MmnXrMPKt5SD0G2mMmSQBcs5LH1oSZQ3IJ9lrZsfBOu3SGY6fKkX96YbB+tSN4dltX2PLEzDqUOR9KdgMqIOzFsbVHTcasMGAPmY2kYzW0nh66eFmiQFOuQMfrWZLaXkchVomOOBtGRj607CKrYRRtHHXGOTURYy7ieFXrirU0LmMbkYfhWbMuwqpkPso70gH7ckhcljwBjpXaeDvDrzvG88ZdsjC46+59KoeE9DfU7xC4baPQ4/WvWbWxbSvJW2hV3xl5pTwo9BQtRFv+yjYwLKZcTsAoRCD/8AqFFOglb7W/nQB5zxHt+YKPXHrRVAfNkWS/fp3odTjDcLntSbGB+YkeuKRiygCMkj3qCh688Ngj1pCQDkHHalO0ggqMnqRSFQMAt9OetADjnGCevIpAPlPPH0pMsx9h2PapBwABxQAwkjA29qX73G7BFCjn5Qc+/FP+YDPX1oAaoKZYcimSlmOAowetWllUJ8uPpUDXHBGFoAZax7m2yHjtmuls5UEWx1B4wDjpWPpiLO4V8qCeoXOK2m0+ZBviuElX+7jGKaEdJoVtpzIHnMscg/iQgH9as6i2ksUCXzXD5wVlXay++apeH9VjiIgvlaJcgbigkX8jWx4isdGuoUntljmBGD5Q2/mO1UhGIVt47gmMwyoOwlAY/nWpZPayfMFKr3JQZH5da5lrNYySu6Nf4SV5qWCznb94GfGP8AWBuaQ9z0ex8J6J4hRfI1CB5TwYpvk59ulLe/Bu7jlT+znKZ7oWIP415pdT30JWJJZJo15yRgr+NbGi+O9a0gAW2rXQA/5ZSNuH4Zp/ITR1Vz8JfE9l+9jWdl6llbB/SuV1mwutId01ASSMO7tkj869D0P4z3Ny0UN+kpB4ZtxxV7XtMg8URG6RNhA4Zm6/nTVhJHh11ctIuREgA5yuM12Pg+9QWx8uSeMnghXA/Ws7xLoRsiTLFjnHyDmsHTJDpl+JPOaJSfXH86ljsbvjrReRcv+9EgzgYJH1NefJYRxMdx257EdK+i9Dnn1nRS0KCdguAu9QWrzPxTodxFdSG8057fJz1qt1calc83ntY1Y4kRl64IwKqvErH5sKOwFaN6n75VxlB0PU1XkMYOFJ/HrUNDK5j2uFyTmgxjcABj86eA38ADc8nHSn7WxlSceuAKW2wEGzk8MfakVSemAKnETEYY5HsOlWI7dRjfuz22nP50wKTbl6tkY4xSIk0p2wxvI3oBxWxEIYGDOhcj+8MVKt15k++Py0A7ZxSEbvgr4Xa/4jKyb4bSz7yzOAB7CuxvvhJYaRtOo6xDKB1SLnNc1oWpXXnIPtUrKB91GOK7vSWhmglluYWU+qqzsT9TxVJCuZ+n6JolorB7O4MS879hOa6XTte0XRkU6fbWsEhH+tkUPJ+GelcHrlxIG+aW4cscLH5px+OKbZ2MoiDzKkUeeWzyB/OmB3eo6u+sbZb+SSaLoiIFUN+HWsK8sYZSWtLZY3B5ZAZG+g7CqUeo6NZzRwrDLJngtI+C30HYV6JoHieziijQWdrAh4jV25+uBRcDmdDsb4yKj6ZLKh6yS8KP6VvXnhy2uB86maTHKQdAfTNdPqut2skIDmJgRkljtUfhWA3iabZ5dkYY4egYAIg/Hv8AgKoDzjxf4TawYvt+zqwyA7c/kOa86m0//ScR5J6FgOleueLZWmT5naWd/wCLaVJ+g6kfXFcWmmyoDNsdiTkjtSYzf+H9m2nkTNJGqN0MnJJ9AK7XWLoyQCa6kUKn3YxwzH3Pb8K5rwxZXl2N/lIFXAXK/wBewrXkRo3keR0kaPjdgEMf7qj+tJKxJseG45jF5tzN/pUvMcEaABB796K29EVmgiluI/LV1ztPyk//AFqKpIZ8iBiVC7sj3pyZ7E/nUAIz1/Ed6erjb0FZFEmCp5z9aVlBHbHemh8ADkUAjox/SmAK/J7jpkCpQDwTj+YNQuQWyRinrgA7cY/WkBIG554x696eVLLnK/nUIkcDDDI7VH5jFjtWmBaaMFMqQHHeooQol5INOTcy84BHakiUBjlSM96ANe1iUMJEYfQ1ft7lncLuKc4BxmqtkPlXzcL6H/Grwt1BygRSecqOtAjoLK1LFd0PmAj73WplgKzhBaOFHRozg1R0y5LERTeV5nb5sE100eiX9xbGW2tBJn+JZMt+lMRn3GnXFyDxLHkfekGFH1NOs/CcbhVmmaaR+T5cmQfpW1APEccYjh06V4gMMPLLY/Ctiyaa5WNLnTYra4HY5XP1BpgVtL+HEjBWhinljPUMcVsn4XWYlVr0SqvXCAGug8Pz6/ahljMgUdEbA/Lsa6a28S34by760UqOuUBNUrE3Z5+vws8JzghL26juR/CW24rmNU8D3ulXJGm6pI6noDLuFe8tqGjXceJLOKGQjG5kKn86ydV0xZI8xiCWE9mPT8adh3PnXXLa9g/d3u15QcKVyP1Jrmby0ljYPMgbPII+b9a9z8W+EIZ7fzYrJlf1RS4/OuDudHsWxA81xHKvRWwFBqWhoyPDGpzaZKkkUrRt0wCcflXpcGvvrUSwy28V2WGCCuCPzry3ULGWJ9hCytnC7Gz/ACqXTY5rfEjCVXBxtViKWwrHSeIPAcV2sjWOmmJxzycg/TFeWa3oLWMuJoJY3PGCDivYdG167gcJbNtBGMSSAfzp2saHcau5uJYyJCM7/M4/LbinuM8Fks2iI3qw9MnFOe3jfkHb9Of1r0DVvD1wpd3iO1eNxTj8CetcLfwbJmWPzAo6kjrUtWGC2qoCyzLnHQc0xWUZOMjp0yKkiyY9pZcemcUhykgwqP69eKQEUkckxCrznjOKn+xpAgWSdQW6gAkirMUzKuUZlz2xWfLJiYsW3HuKAPUPAY8NWSpLdxSXdwnKiWQRp+I71s+J/E734ZIZ7aOAcLHH0UV5xo8sJg3O0YbsNuamubm3Zdu8qw/ujGaaYjWtL63ZyZ0LMo4YJmszV9UeeNwtxIkf93BJNUku5mXYxyvbJqSVJhHljHEp6EnJoGZMdw0M/CtI+PvHNaunaxLDIpUESev+FY19vEnMrSe4GM02F5Q6hHGevPakB6BZpq+qESOqJCOnmPVky3lvKu2WN2BxuJxj6ViaJ9pljUyySOvTapOPxNdRbxouHmtRPIB8kQB4/D0+tMTG6dNLNcN5EMl5OPvMOI1+rf4USzSIyrcRxNIDkwQcqPqaluLy9eEw7YbcdBDEcsfrirVjoUzqWlIhQDMmw8Ae5pgSDV7tkWPylhQ4G5hhVHsO5rodKghupEecHyU9uB74rJ+ypLbYllMNv91SsZ3n6Cp5Jo7eCKNd8EC8IjDdJIfXH+NMRr+ItRht4yiOELcYzliPc9hRWZdW0CWTSSxKJGGcO25ifc/4UUxnzS2SeMAe4pOnGePakAB+8T+dGACRjNZFDtwPXIx6U5WJ5649aZ1ydpwBzQOnPH4UATDJ5DE05cgZbP4moVOW4yKeWXaCCcHt60AOIPJB4P40Lhc9MGiAkfdAzT3RTz91/SgAh3F9oHXpitCztlL4kYp6Bv8AGo9NaSGQHaPx716boEujajaLFqMaJLj7wWhCucVDELU7osyj+IAg4rVt4FuMFZGiU9cjIH+FdUvgW11CRhp18uW5VAp5/CqiaReaLeGDUpVi9N8RAI+uKqwrkVlpEwxmC0uoj1+Yq1Sm+uLO4MFmbi0Zem1yf1Na1nqcFrJsRBKOrLuyD9BWzF4h0eUjOkRTSqMFBkGnYB/hvxnrFoUN3cOYFX74Qtn61f1bx+brKh7dx/dkT5j9KypZdPlkNzZ7LbPLQSlsfTpXP69qFlNnFlFvHBaI/wBaaA7HSvGkULiO6kuo427OBIB9M9K7DR/E9nK+VKSxk4YkncPwGRXgVre3lvmSAsIx/C7BgPzq/Z6pb3k2LlfJf+/Fxg/QUriPpM6hp8mDGZAp6iSNiP5VF/a+lQZDGMr6Kuf8K8YttevLa2CWmo2d1EowVlVg1Yt54lvQ5b7JGy55aEEAfnV3Cx9FWklnftm1VFTuMYzWLrnhGylla4W1TJ6lSCf5V558P/GBa6WOeXywxAGQMD68V7i8U19YBoDFIduQVbr+lCdxM8b1jwJY3BJheVJ15AHy4rltU8K6rpUXnBLp4e+JFNera7pWoabA9xJCuASxIJOPzqK2klntYvLt7WUuP+Whxmk0M8Vhnt4LlZbiWWR9wG3+7+HSvQ9HvJHgV7JhPkf8t+dv4CtHW/BCTD7U0VvHKf7i5/nXI3cVxpVwVRQ4PRlYr+nSlawzV8TWtvdWpe+nti68lS5A/Ic14xr9oJriSWIKsYOF5wK9Dud2oEzsGIU/KHkyAfp0rn9XRZRl0cMP4gQP0obuCOFVWgPzq59OeKSQhcPlee3ety4gj83d+9zj+PvUbRK65kRSB/e4qRmP5q7MAMSegBrPkiUMWKHd6Zxitm6BGNioBn+EVnXTHBGTu9h/WkAtnKUbCBvpVqNHmnLOSQPU9KxkkdZCCCQeDt61rWsxDIrRSYz93g0XA6Kwtw0YaNA3+0Rmm3dqJVzIjyY7AYArptHurUWkcVxG0cRXllIX/wDXUGq/2e4Ist5I/ikbP5CmgOIutPeR/lRvp6Cm2mmO023y+PfmuwsrHz4Sod5Hbjc3AH4Ctq302KztFDRkykfeZgv5DvQK5zVsl5DGkUMMhU8ZY4B/Lk1u20LWse24Z1U/fQNtzTNk7XJWKdogeMhf5Uk9nNp6NIilmP8AFNz+OKYHT6OBcoy2NrBbQL9+U8t+FWpLvzdtvDKyRx5wkYxn3JrK8PW+o6oFV1k8v+8flB/4CK09W063tEWOW7kZV5cQDk+2aYEEupSSPHFbQ/abgcLGuT+NKbS6hB1LWY1Xy+VTOFU+7f4VK+rtb2Pk6FaeTkfM235j/vGuY1Wzv9TZZr28uLt15CJkRp9KQEt9rCXCTTSz+XngKozgfjRXN3WlOTt8tyq8syjCj8TRTuM8vIwASQT3FKOW4/CkGTnCjHvSggfKWyD04rMYoBX5iTn3oIx8zEc+9KpOMkcHjijPJ3A8e1AAOSNuTj3pxbBwAfxpMgqVCcH3/lQB0HQj3oAcj4JyxY08sSOWOc1GG6DHI74oLF+CvSgC9aM5YLuGPQjNbdoGjdW83a1c/bu6keWvHvXRWMMkka+aR69M0CO90DUkZUOSki/xD5R+lei6fqtvqNssOpSSTRgfxKHx/WvDk+0Kw8tQw/2Tg/lW7Y6xcRR+X+5Dj+8u0/nVJ2FY9Xi8MadPJ52nSA56I8YI/wARRqGiWFnA5vNPhSTs20kH6EV5uPEmoxqNwYp/eTr+YqOfXbq5AaO5mJXnbKTx+tVdAT60wS4MRTEbdDGGTH59a5bU0QRt+8zg9gQa17zXLqeAwPch17oR0+lczqbKCp3sB3zzSuMrxXs/3AFCDoTVmGWSNNxnjAPfZ/XFUN8e3jLD6Gmeeo4MbAeoNSBqCectuVmY9ipxUb6hPCHDebGT3LVW3+XHmOSQ99u6qFxPJIf41/3mp3A6HSNUe3uVMrqVyCexr6J8BeL4XslTafLAA+Ymvk1ZVAw7856g16T8Ob6RJwWlEiccUk7MmSPpuS9gvVIMr8/wgAiud1nT/m3mW9T0MQx/KmaRrcMUaK9qST/EpBP8q0LvUZbpMQQuvYN5oBrVO4GTHpdxcAK8lzLnoHYg1man4Uv3kJeBvLH3VYn+nNb8d/LbbcD99n70j8/pUV14lhClL6+jil7BVJP60wPP9V8O6hbOFt7VRu6Z4wfb/Guf1fQrizkX7esQcrksJ/u12l/rP2kttmjl2njcpwfyNcnq/mXgM0KQgjrk/KPwqWM4+4sE3k+crZPI3EiqN7FII+OVHQjgVsxwbpil3IsaZ6oODU96ugxW5j+0XEsoH3RzUDONdPlJJYf7TcVTmRXDKuGHqBk10M1tHIpNvE+T3YVg6ijQnCBuevNAGNL+7mAjGB3rotEht3YedOnrgHpXOyzryoT8SKsaZKqzBw2T09qlgz1vw9Dbs++Yh7cD7zgVJq02llC1opI5/g4rB0fU1+zLbxxzXdwegVMqPwrQm8N6zdJ9ou9Pv5B2BXYgq0IzmvxuXyJNm05AHzMfoOgrodEt/tNysly/lBurtycexPSqfh3wjdX2possqWwJ+5GdxAr3jQfBWnw2SKINzKMNNMRn8KSQrnnbwadGPKssSS4yQrb2/PoKor4e1O8cmzs2LZ+v/jxr2+38O6Xa4aO1hHoSMlvfHel1OaysIC108cSjsTjH4Cr5RXPJdK8N663yXkkdhDn5l35Yj8K2ZdLtbVVdY5Z3AwHmO2MH1x3pNZ8cWNnMVsI/NduBIwyPwFcpLr95eXbzXMjOzfcEiZCfQdKNijpJr7T9NgeWcQTSfwpwi1lXupR6jb7I0+03B5FrZr8q/wC+/pWLK+nMC+rTzXUp6Rr8v/1hVfVtbni0zyLFotLsm6xW4zJIP9putG4HK+KbuaJ2iu51kmGcW0J+VPYmiub1a7jV32DaT/ExyxoqXuM44cj1pvtn9Kz45Wj6cj0NWY7lD94Ffp0qBllhz0NJhjjBOB3NC88jH1ByaVs9yKAFDYOBjnrxTlzk8q2PXiowoH9KXI3c8fh1oAlRlI6fhSAEMQQPxNN3Jgf40Iu8c8Ed6ALFvKI+OPXGa37WVpIhsXHHp/WudRRvBYNgfxDtW1YyxcKHYGgVi1JMY9pkdkPsTVuCd+oudyHqpGadHJZFSJiG+oqvObJQTADkf3TTAvpdLFgQz+UxPRs4NRXcrQOs0mJWPdGzWJNfgNjHB9aZ9oTnlyv16UwNC41OSRjsXaD3rPmvWZsHLH1I6VWdwxOS2PTPSmblAPJz6jk0hk63LjP7wY9CKmju5SMHBx221RWYn0J9zTmd8Y8zj24oAui7dc4G0+3aqU00jP8AMWbP6U1jkgnPHvTZWjkfqAD9aAFRFlOFBGOua6XwzdS2cyFDn2zXMBEHOQy/7PWtWxvjDgo2AOnNITPbfD3iDfKnmhtuP77Dn6V0d9q0ypvhLNHj7oc14hZ6xfuQqyfJjj5M1eF7eDhrnA7gk1aYrHodzrwVSyW8gkPcsR/KuZ1LW2uZv9KR5FHZeR+tY8d4CwEkvz9sZps0shc8uQe4H+JpthY3LHWbVWzJZTsR93EoA/QUa/qsrW+VtljiI+5vY5+prlDcSQOZFuCEB5G0H+VPu7+S5tsoGZce4NJMCpPf3cjYMCqg/hUcVTdjy7MgOeg7UNK7khpNi9MHqaikkRPlQE59qTGWRI80ZaV5JAB3YgCsu7k2xlhux7GrII8s7gwHpk4qnKC52s52/wB3GBQBjt5s8hwAFzWzpEMPmqphMxz24qEtHDwIix9TwKs6RqrWUxeIRBvXbk0hs9j8JTalpEAfSdLsrd3AxLKu9h9BXYwWr6nH9q8TancXD9oS+yMf8BFeBSeKL6VlaaY7R0QZVf8A69PuPEF/IoLyBU7bmP8AKmnYmx9BWet6doz7xJa2sI4AVcs2K2JfiFpjIAtysgxnDNgflXyzPdXU37x5xj3NVYbphIS0hA7nPWncLI+ldS+KVtETFbXCh8clF6f1NYd5rs91/pctsHUjiS8fI/AdK8a0+9EcubWISHPTG413OhS/ayLjUQzt0EYI4/E8CmmLYg1fXZTdCREFy3YRLsQfj1JqpJrF9K/zLFDx/q0GP5966bUfEWi6VbMZFh8wD7kXLf8AfXX8q8o1zxBJd3bPbRGBCeB3oY0dRdSzQjz72RIEPIVm+ZvfHWua1PxDLIzLaqip3lYZJrBvbqLPmXk25j/ADkmsi61EPlYE2p2Lf4VFx2NSedRmWWVcnoTyaK5p2LHLEk+9FFxjaKKKQDldlOVJBqwlz2kUEetVaKANNZ0cBUOG9xUpX5fUY5rHqVZpFxhjj0NAGmAAgKgMD2IqSNg+VACkdRiqCXmD8wP1BqzHNE+MOA3vQBcXKLwABUhfdjKgH1FQbum0ZHqDT84UhRj2Y0ATrIy9zn86f58m75XH0NVUbjBY/hxinJI2SBjPbpzQBNNyMlRu+gqBriXBAIX6U9mDfeBBHoahkJIxtJx3pgICQud2T6g9aAWY8EqR19KQMOex/OmZIyS2QfbikA8vjgr+VKrZ+8Dj2NRA5HynPtQcr1b8uaALG9cnAOD70jyqw2qDgDrVdiQQylSB6Dmk3Fun3vpQA8E5yGx+NWYZWVhtI/CqLEgFTx9DUsHUZOT2oA6CzuFjIYl1Pu1aZuWmXCSt/wB85rmo38sg4YVoLMXQbd+fUE0xGuLnykwwYnH3tuKrLeBXPQg/3mNUWxInLOSPVuKrSTIpxK4wP9sUwNQXcSORCvJ685qb+0m8oxmfHsM5rFjuFlYi3XLDoR/jWgt3PBGBIg574FAEDz/vDs79Sacjqx3fNj9KqXE3mNle59KfFKyHJC/8C60gLv7zaSHOPQ4wKpXUs78KwK+oq8plmAz93sI1x+dQsHUkuiMPc9KAMKZucEbgD3NQ7l3jAH0zVy6jEjlwMD8apGIqe2e2KBly3l5PTI75qeNwH3ONwHdjVGBWRhlQB35zV1I0YBpXAx2x/IUgHyXRd9qDj3GKlhXzM+a2F9KrTvDGm5s7B/F0NVDqVvGpwXc+g6UwOhgunt1It22oOp6frUxv7mOBm+0tGp98D8zXGyarMSfKCoPzNUpppZmzLIznryc0AdDe6xboCsZM8n9/PH51iTX80rE7iufQ/wBaqUUXAcTk5PJptFFIAooooAKKKKACiiigAooooAKWkooAkWaROEdgPTNTrfSjGcH3xzVSigDVXUVOAynHfvUwuon+6y/TpWLRmgDbOSAyHr6UsjfKPNOD27ViBiOhI+lSC4mH/LQnHrQBpkkdF57E96MdC/3umB0qit7KODgj8qkF6AmCnzdzmgC2o2kgYz6d6THYhs+9QJeRfxK31py3ML8MSPTrQBMQFGG/9BpCTjOQfY0w3SDCrKCPpimExv1lT8TQAuVY8LlqsQB3bOBkdATUKlWHytH8vQ5rQsSjY37X9zigB0UFw7AiJ1b+9nitzSvCuvapMqWoUo3vS6b5YcHztg/D/Gu80e8RYAf7Qi2DqPMCsf1oWpJHpfwN1S8AbUdRitk9Ayn+tdvonwD8KKAdR1l3k7gEA1zh8SaHDKA2qWkMqnDeZKHIP5nFdHY+OvC1tatJcarZShBliLvn8FHJ+gFUkhamvP8ADPwhpLCPTDc3M+OqxZA+prJ1HwLpUqEXRctjpgLj8BzVuL4x+DbaAhNXCEDOyGNyP/Qa4nxJ8ZtDuo5DYi5dyOPMgwT+OeKu6GrmH4o8NaNp5b7KkkpB5bJzWJbjSbdP3ltuc8ZLtn8hWNrfjZL/ACY4ZeT/ABHFYT6/IrZihQcdWJOTUOw7Hb3C2mSYdyA9x/8AXrOniEgeOEsx9SRXJS69fMQVeNCP7qD+tU5tQvJseZcytjp82KVwN2+QRviRlOOvzVnPdQAEAk9/lrKLE9TmjNAy8NQKjhMn1JqF7yVs/Ntz6VWopAPdy/3iT9TTKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKMUUUAGB6UYHpRRQAUUUUAFL9aKKADikoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stuck donor twin at 21 weeks of gestation. Arrow denotes the donor twin against the left upper quadrant of the uterine cavity. Note that the calipers indicate a maximum vertical amniotic pocket of only 1 cm. The cord can be seen with color Doppler adjacent to the abdomen of the donor twin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36790=[""].join("\n");
var outline_f35_59_36790=null;
var title_f35_59_36791="Pseudoephedrine and ibuprofen: Drug information";
var content_f35_59_36791=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pseudoephedrine and ibuprofen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/63/8181?source=see_link\">",
"    see \"Pseudoephedrine and ibuprofen: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/46/31462?source=see_link\">",
"    see \"Pseudoephedrine and ibuprofen: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advil&reg; Cold &amp; Sinus [OTC];",
"     </li>",
"     <li>",
"      Proprinal&reg; Cold and Sinus [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advil&reg; Cold &amp; Sinus;",
"     </li>",
"     <li>",
"      Advil&reg; Cold &amp; Sinus Daytime;",
"     </li>",
"     <li>",
"      Children's Advil&reg; Cold;",
"     </li>",
"     <li>",
"      Sudafed&reg; Sinus Advance",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Decongestant/Analgesic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Analgesic/decongestant (OTC labeling):",
"     </b>",
"     Oral: Ibuprofen 200 mg and pseudoephedrine 30 mg per dose: One dose every 4-6 hours as needed; may increase to 2 doses if necessary (maximum: 6 doses/24 hours). Contact healthcare provider if symptoms have not improved within 7 days when treating cold symptoms or within 3 days when treating fever.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F215446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/46/31462?source=see_link\">",
"      see \"Pseudoephedrine and ibuprofen: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Analgesic/decongestant (OTC labeling):",
"     </b>",
"     Oral: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F215442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Cold &amp; Sinus, Proprinal&reg; Cold and Sinus: Pseudoephedrine hydrochloride 30 mg and ibuprofen 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid filled:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Cold &amp; Sinus: Pseudoephedrine hydrochloride 30 mg and ibuprofen 200 mg [solubilized ibuprofen as free acid and potassium salt; contains potassium 20 mg/capsule and coconut oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Caplet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6740179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     May be administered with food or milk if stomach upset occurs.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For temporary relief of cold, sinus, and flu symptoms (including nasal congestion, sinus pressure, headache, minor body aches and pains, and fever)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ibuprofen, pseudoephedrine, or any component of the formulation; hypersensitivity to aspirin or other NSAIDs; use with or within 2 weeks of discontinuing MAO inhibitor; immediately prior to or after coronary bypass graft (CABG)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding/hemostasis: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: NSAIDs are associated with an increased risk of adverse cardiovascular events, including MI, stroke, and new-onset or worsening of pre-existing hypertension. Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation. These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol (&ge;3 alcoholic beverages/day), the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue at the first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery: Use is contraindicated when used immediately prior to or after coronary artery bypass graft (CABG) surgery. Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or urinary obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs even at low doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for self-medication (OTC use) in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Prior to self-medication, patients should contact healthcare provider if they have had recurring stomach pain or upset, ulcers, bleeding problems, asthma, high blood pressure, heart or kidney disease, thyroid disease, diabetes, glaucoma, enlarged prostate, other serious medical problems, are currently taking a diuretic, aspirin, anticoagulant, or are &ge;60 years of age. Recommended dosages should not be exceeded, due to an increased risk of GI bleeding. Stop use and consult a healthcare provider if symptoms get worse, newly appear, or continue; if an allergic reaction occurs; if nervousness, dizziness, or sleeplessness occurs; or if fever lasts for &gt;3 days, congestion lasts for &gt;7 days, or pain &gt;10 days. Consuming &ge;3 alcoholic beverages/day or taking longer than recommended may increase the risk of GI bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F215447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response.  Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5201399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     May be taken with food or milk if stomach upset occurs. Some products may contain potassium and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Advil Cold &amp; Sinus Liqui-Gels Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-200 mg (32): $9.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Childrens Advil Cold Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-100 mg/5 mL (120 mL): $6.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Childrens Motrin Cold Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-100 mg/5 mL (120 mL): $5.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Advil Cold/Sinus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-200 mg (20): $5.69",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Advil Cold &amp; Sinus (IL);",
"     </li>",
"     <li>",
"      Advil Cold-Sinus (EC);",
"     </li>",
"     <li>",
"      Arinac (IN);",
"     </li>",
"     <li>",
"      Brenfed (IN);",
"     </li>",
"     <li>",
"      Dayflu N (PE);",
"     </li>",
"     <li>",
"      Dristan Sinus (CO);",
"     </li>",
"     <li>",
"      Nurofen Cold &amp; Flu (NZ, ZA);",
"     </li>",
"     <li>",
"      Rhinureflex (FR);",
"     </li>",
"     <li>",
"      Tri-Profen Cold and Flu (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/59/36791/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10236 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36791=[""].join("\n");
var outline_f35_59_36791=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215437\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215438\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215450\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215441\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215446\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215442\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215430\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215419\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6740179\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215431\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215448\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215434\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215422\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215447\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215426\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287338\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287340\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5201399\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323753\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038791\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215433\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10236\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10236|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/63/8181?source=related_link\">",
"      Pseudoephedrine and ibuprofen: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/46/31462?source=related_link\">",
"      Pseudoephedrine and ibuprofen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_59_36792="Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection";
var content_f35_59_36792=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/59/36792/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/59/36792/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/59/36792/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/59/36792/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/59/36792/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/59/36792/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/59/36792/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    dipivoxil (Hepsera) is a nucleotide analog of adenosine monophosphate, which can inhibit reverse transcriptase and DNA polymerase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Adefovir has been evaluated as primary monotherapy for patients with chronic hepatitis B and in patients who developed resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . It was approved by the FDA based upon the results of two phase 3 clinical trials in patients with HBeAg positive and HBeAg negative chronic hepatitis B and a compassionate use protocol for patients with decompensated cirrhosis or recurrent hepatitis B post-transplantation and lamivudine resistance. Several other studies evaluating adefovir in other populations have also been performed.",
"   </p>",
"   <p>",
"    This topic review will discuss the treatment of chronic hepatitis B with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    . A general approach to patients with hepatitis B (including other treatment options) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HBeAg POSITIVE CHRONIC HEPATITIS B",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    in HBeAg positive patients has been demonstrated in at least two large, placebo controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The largest included 515 patients with compensated liver disease who were randomly assigned to two doses of adefovir (10 or 30 mg) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/3\">",
"     3",
"    </a>",
"    ]. The study was open to treatment naive patients as well as those who had failed interferon. The following benefits were observed compared with placebo in the 10 mg group (the approved dose) after 48 weeks of treatment; all results were statistically significant:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Histologic improvement, defined as decrease in Knodell histologic inflammatory score by at least two points with no worsening in fibrosis (53 versus 25 percent)",
"     </li>",
"     <li>",
"      Improvement in fibrosis based on ranked assessment (41 versus 24 percent)",
"     </li>",
"     <li>",
"      HBeAg seroconversion (ie, disappearance of HBeAg and appearance of anti-HBe, 12 versus 6 percent)",
"     </li>",
"     <li>",
"      HBeAg loss (24 versus 11 percent)",
"     </li>",
"     <li>",
"      HBV DNA reduction to &lt;400",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (ie, undetectable levels by the Roche Amplicor assay, 21 versus 0 percent)",
"     </li>",
"     <li>",
"      Percentage of patients achieving normalization of ALT (48 versus 16 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HBeAg seroconversion and histologic improvement were more likely in patients with higher baseline ALT values.",
"   </p>",
"   <p>",
"    The group that received 30 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    had a higher rate of HBeAg seroconversion (14 versus 12 percent), but the difference was not significant. Furthermore, the 30 mg dose was associated with an increase in serum creatinine (&gt;0.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    in 8 percent of patients.",
"   </p>",
"   <p>",
"    A follow-up report described efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    in a subset of 65 patients who received the 10 mg dose and were observed for up to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/5\">",
"     5",
"    </a>",
"    ]. Of 41 patients who were still receiving adefovir at five years, median changes from baseline for HBV DNA and ALT were 4.05 log",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and 50",
"    <span class=\"nowrap\">",
"     unit/L,",
"    </span>",
"    respectively. The probabilities of HBeAg loss and seroconversion were 58 and 48 percent, respectively.",
"   </p>",
"   <p>",
"    In 15 patients who had a repeat liver biopsy, improvement in necroinflammation and fibrosis were observed in 67 and 60 percent, respectively.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    resistant mutations (A181V and N236T) developed in 13 patients (30 percent). Nephrotoxicity, defined as reproducible increase in creatinine by &gt;0.5",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    was observed in six patients, and two patients had confirmed hypophosphatemia.",
"   </p>",
"   <p>",
"    One problem with this follow-up report was that, due to drug misallocation during the second year, only 65 of 171 patients were included in the long-term follow-up study. Furthermore, all 65 patients were off treatment after year one. Treatment was resumed after a median of 16 weeks (range 3 to 70 weeks). All but one patient had misallocation of drug in year two to three. Serological response was assessed by Markov modeling and not actual patient data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Durability of HBeAg seroconversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBeAg seroconversion appears to be durable in the majority of patients. Data from 45 patients with compensated HBeAg positive chronic HBV who achieved confirmed seroconversion to anti-HBe and undetectable HBV DNA while receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/6\">",
"     6",
"    </a>",
"    ] showed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HBeAg seroconversion was sustained in 41 (91 percent) patients after a median follow-up of 150 weeks (range 13 to 252). However, only 45 of 82 patients with confirmed HBeAg seroconversion were included in this report.",
"     </li>",
"     <li>",
"      Among the 41 patients with durable HBeAg seroconversion, the median duration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      treatment prior to HBeAg seroconversion was 48 weeks, and the median duration of treatment after HBeAg seroconversion was 41 weeks. By contrast, the four patients who did not have durable HBeAg seroconversion had a median of 108 weeks of treatment prior to and a median of 22 weeks treatment after HBeAg seroconversion. It is not clear if a short duration of consolidation therapy or a slow response accounted for the lack of durable response in these four patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HBeAg NEGATIVE CHRONIC HEPATITIS B",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adefovir monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A controlled trial included 185 patients with HBeAg negative chronic hepatitis B who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    (10 mg daily) or placebo for 48 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/7\">",
"     7",
"    </a>",
"    ]. At the end of treatment, patients who had received adefovir were significantly more likely to have improvement in liver histology (77 versus 33 percent) and undetectable HBV DNA (51 versus 0 percent) and normalization of ALT levels (72 versus 29 percent). No treatment-related adverse events were observed.",
"   </p>",
"   <p>",
"    In a follow-up report, patients who received placebo in year one were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    , while patients who received adefovir in year one were re-randomized in a 2:1 ratio to adefovir or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, there were three groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Group 1 (79 patients) received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      for a total of 96 weeks",
"     </li>",
"     <li>",
"      Group 2 (40 patients) received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      for 48 weeks, and then placebo for an additional 48 weeks",
"     </li>",
"     <li>",
"      Group 3 (60 patients) received placebo for 48 weeks, and then",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      (10 mg) for an additional 48 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    through weeks 49 to 96 were subsequently offered continued therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    was associated with a median decrease in serum HBV DNA of 3.47 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at week 96 and 3.63 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at week 144. At week 96, HBV DNA was undetectable in 71, 8, and 76 percent and normalization of serum ALT in 73, 32, and 80 percent of patients in groups 1 to 3, respectively.",
"   </p>",
"   <p>",
"    Side effects during weeks 49 to 144 were similar to those during the initial 48 weeks.",
"   </p>",
"   <p>",
"    These data indicate that responses are negated in almost all patients after treatment is stopped after 48 weeks.",
"   </p>",
"   <p>",
"    An update of this study included data on 55 patients who completed four years (Group 3) and 70 patients who completed five years (Group 1) of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/9\">",
"     9",
"    </a>",
"    ]. Based on modified intention-to-treat analysis, normalization of ALT was observed in 73 and 69 percent, and undetectable-HBV DNA by PCR assay in 73 and 67 percent, respectively. Forty-six patients had repeat liver biopsies at the end of the study. Ranked assessment of liver histology indicated improvement in necroinflammation in &gt;80 percent and fibrosis in &gt;70 percent of patients in both groups. Significant improvement in fibrosis (a decrease in fibrosis score by &ge;2 points) was observed in 7 of 12 patients who had bridging fibrosis or cirrhosis at baseline.",
"   </p>",
"   <p>",
"    The cumulative probability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    -resistant mutations rtN236T and rtA181V increased from 0 in year 1 to 3, 11, 18, and 29 percent in years 2, 3, 4, and 5, respectively. Four (3 percent) patients had confirmed increase in serum creatinine by &ge;0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    above baseline; nephrotoxicity resolved in one patient after permanent discontinuation of treatment, and remained unresolved in the other three patients.",
"   </p>",
"   <p>",
"    These data indicate that treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    for four to five years is associated with maintained virus suppression, ALT normalization, and improved liver histology in 65 to 80 percent of patients. However, rates of adefovir resistance increased progressively to almost 30 percent. Although nephrotoxicity was infrequent, the persistent increase in serum creatinine was concerning. Thus, regular monitoring of renal function is mandatory in all patients receiving adefovir.",
"   </p>",
"   <p>",
"    When all patients in the original phase III trial were considered, 6 of 183 (3 percent) patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    developed HCC, and all except one patient was diagnosed after 48 weeks of treatment (range 112 to 219). Five patients had substantial necroinflammation and fibrosis prior to treatment. Serum HBV DNA just before HCC diagnosis was 5 log10",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in one patient, 3 to 4 log10",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in four patients, and undetectable in the sixth patient. Only one of these six patients had adefovir resistance. These data suggest that antiviral therapy does not completely prevent HCC, and HCC surveillance should continue in at risk patients. This observation was supported in another study (reported as an abstract) of 124 patients with cirrhosis due to HBeAg positive chronic HBV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/10\">",
"     10",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or lamivudine plus adefovir suppressed HBV DNA replication and prevented clinical decompensation for at least five years but did not appear to prevent the development of HCC. HCC developed in 22 and 29 percent of the two groups, respectively.",
"   </p>",
"   <p>",
"    A report of 33 patients without cirrhosis who discontinued treatment after four to five years of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    and were followed for 5.5 years found that all patients had viral relapse (detection of HBV DNA by PCR) and 25 had biochemical relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/11\">",
"     11",
"    </a>",
"    ]. During follow-up, 18 (55 percent) patients achieved a sustained response (HBV DNA &lt;2000 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    and normal ALT), and 13 cleared HBsAg. These data suggest that sustained clinical remission can be achieved in more than 50 percent of patients with HBeAg-negative chronic hepatitis B after four to five years of continued antiviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HBsAg LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clearance of HBsAg with appearance of anti HBs is generally considered to represent clinical and serologic recovery from chronic hepatitis B. The frequency with which this occurs following treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    was estimated in a retrospective analysis of 578 patients who received adefovir monotherapy during their participation in four clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of HBsAg with appearance of anti HBs was observed in nine patients (1.6 percent) after a median of 73 weeks.",
"     </li>",
"     <li>",
"      The median time from loss of HBeAg (among seven responders who were initially HBeAg positive) was 32 weeks (range 16 to 88 weeks).",
"     </li>",
"     <li>",
"      HBV DNA levels were undetectable by PCR, and serum ALT was within normal limits in all patients at the time of HBsAg seroconversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data indicate that HBsAg loss is infrequent after one to two years of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATIENTS WITH LAMIVUDINE RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV infection has been demonstrated in several clinical settings. The available data suggest that adefovir is associated with significant clinical improvement and reduction in HBV DNA in patients with all types of lamivudine-resistant mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/13-17\">",
"     13-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Liver transplantation and decompensated liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in the transplant setting and in those with decompensated cirrhosis suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    is effective in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistant hepatitis B. Adefovir is sometimes used as a first-line antiviral agent in the transplant setting. However, the antiviral effect of adefovir is slow, and as many as 25 to 50 percent of patients have primary non-response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, viral response should be closely monitored and alternative treatment considered in patients who have minimal viral suppression after more than six months of treatment. For patients with severe decompensation, options include de novo combination therapy with lamivudine and adefovir or newer therapies such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , which are more potent and have lower rates of drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=see_link&amp;anchor=H9#H9\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\", section on 'Decompensated cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Emerging data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    should be added to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in patients who develop lamivudine resistance in an attempt to minimize the development of adefovir resistance (similar to the nontransplant setting) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The largest study (reported as an abstract) included 68 patients who were followed for an average of 18 months after transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/19\">",
"     19",
"    </a>",
"    ]. Fifty-seven patients had received prior treatment with lamivudine of whom 42 had breakthrough infection due to resistance. Of these, 12 were switched to adefovir monotherapy, while 45 received combination therapy with lamivudine plus adefovir.",
"   </p>",
"   <p>",
"    Only 54 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    achieved an initial virologic response (defined as serum HBV DNA &lt;4 log",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    after six months). The cumulative rates of adefovir resistance at month 12 and 24 were 0 and 15 percent, respectively. Resistance was significantly more likely to develop in patients who were treated with adefovir monotherapy (100 versus 15 percent) and in those infected with genotype D. Three patients who developed resistance developed viral rebound, two had a hepatitis flare, and one patient died of decompensated disease.",
"   </p>",
"   <p>",
"    Further studies are needed to determine the long-term safety in patients who are prone to renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/17,20,22\">",
"     17,20,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15402?source=see_link\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Compensated liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    is effective in patients with compensated liver disease who had developed resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Adefovir should generally be added to lamivudine since most patients will require long-term treatment, and combination of lamivudine and adefovir reduces the rate of resistance compared to adefovir monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/10,19,20,23-27\">",
"     10,19,20,23-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     HIV coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    (10 mg daily) was added to the existing HIV regimen (which included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    150 mg twice daily) in a group of 35 patients who were coinfected with HIV and HBV and had developed lamivudine-resistant HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/15,28\">",
"     15,28",
"    </a>",
"    ]. Of the 29 patients who completed 144 weeks of treatment, HBV DNA levels decreased by 3.98, 4.81, and 5.45 log10",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at weeks 48, 96, and 144 respectively. These data suggest that additional viral suppression can be observed with continued treatment. None of the patients in this small series experienced rebound in serum HBV DNA level or was found to have adefovir-resistant mutation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    was well tolerated in the studies discussed above. The most common adverse events were asthenia, headache, and abdominal pain. Renal toxicity (a concern with the higher doses of adefovir) was uncommon in patients receiving the 10 mg dose except in those with decompensated cirrhosis or who had undergone liver transplantation. A reproducible serum creatinine increase of &ge;0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    was observed in 15 to 22 percent of such patients by week 48, although many had preexisting renal dysfunction and were also receiving other nephrotoxic drugs. In the non-transplant setting, renal toxicity was observed in 3 to 9 percent of patients after four to five years of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. Renal toxicity appears to be more likely in patients who are older, have baseline renal insufficiency, have hypertension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/29\">",
"     29",
"    </a>",
"    ]. Renal tubular dysfunction was observed in up to 15 percent of patients in one study of 42 patients treated for a mean of seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/30\">",
"     30",
"    </a>",
"    ]. The manufacturer recommends adjustments of dosing intervals for patients with renal insufficiency and periodic monitoring of renal function (such as with a plasma creatinine, phosphate and urinalysis). However, the efficacy of the dose reduction strategy in maintaining viral suppression has not been well studied. Renal tubular dysfunction may be partially reversible with a change to other antivirals.",
"   </p>",
"   <p>",
"    Exacerbations of hepatitis (serum ALT elevation 10 times the upper limit of normal or greater) were described in 25 percent of patients following discontinuation of therapy. Most events occurred within 12 weeks of drug discontinuation, and most cases were self-limited or resolved with reinitiation of treatment. However, severe hepatitis exacerbations including fatalities were reported, particularly in patients with advanced liver disease. Thus, patients should be monitored closely after discontinuing therapy. Resumption of hepatitis B therapy may be warranted in such patients. Hepatitis B therapy should be resumed promptly in patients with severe exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DEVELOPMENT OF RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance occurs at a slower rate during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    treatment compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . Several mechanisms have been suggested that might contribute to the low rate of resistance to adefovir. The adefovir molecule is structurally similar to dATP, which limits steric discrimination by HBV polymerase. The phosphonate bond in adefovir may be less susceptible to chain terminator removal once the molecule is incorporated into viral DNA. In addition, its flexible molecular structure permits it to bind HBV polymerase even in the presence of minor alterations in the nucleotide binding pocket. Resistance has not been detected in patients during the first 48 weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, mutations conferring resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    (rtN236T, A181V, and A181T) have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. A study analyzing pooled data from all studies sponsored by the manufacturer concluded that A181T mutation was not associated with adefovir resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/36\">",
"     36",
"    </a>",
"    ]. The rtA181T mutation leads to a stop codon mutation in the overlapping surface gene with resultant impairment in virion secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/37\">",
"     37",
"    </a>",
"    ]. This may account for the low serum HBV DNA level associated with initial emergence of rtA181T mutation. Another study reported an association between a mutation rtN233V and primary nonresponse to adefovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/38\">",
"     38",
"    </a>",
"    ], although a subsequent report found that this variant was not resistant to adefovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cumulative rate of resistance was estimated to be 15 percent by 192 weeks in one report that included data from five studies, including three studies of patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV, most of whom received a combination of lamivudine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/40\">",
"     40",
"    </a>",
"    ]. In one of the studies cited above in which 67 HBeAg negative nucleoside na&iuml;ve patients received adefovir monotherapy, the cumulative rate of resistance was 0, 3, 11, 18, and 29 percent at weeks 48, 96, 144, 192, and 240, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/9\">",
"     9",
"    </a>",
"    ]. In the study of HBeAg positive nucleoside-na&iuml;ve patients, the cumulative rate of resistance was approximately 30 percent after five years of treatment.",
"   </p>",
"   <p>",
"    Studies using more sensitive techniques to detect antiviral-resistant mutants reported much higher rates of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    resistance in patients with prior",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance: 19 to 32 percent at 48 weeks and 58 percent at 96 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/18,41\">",
"     18,41",
"    </a>",
"    ]. Whether this is related to switching patients with lamivudine resistance to adefovir monotherapy or to increased sensitivity of the assay is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recognition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of resistance is generally heralded by a rebound in HBV DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/40\">",
"     40",
"    </a>",
"    ]. Virologic breakthrough may be followed by ALT flares and, in rare instances, hepatic decompensation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lack of initial virologic response should be differentiated from virologic breakthrough due to drug resistance. A retrospective analysis of the degree of initial virologic response in the phase 3 trial of HBeAg positive patients found that 25 percent of patients had a less than 2.2 log10 reduction in serum HBV DNA level after 48 weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/43\">",
"     43",
"    </a>",
"    ]. Baseline HBV DNA sequences from patients with suboptimal viral suppression did not differ from those with good viral response, indicating that host factors may account for the variability in viral response and suboptimal viral suppression does not necessarily mean that the patient has pre-existing antiviral resistance. One study suggested that patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistance who have a suboptimal response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    (10 mg daily) may respond to a higher dose of adefovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/44\">",
"     44",
"    </a>",
"    ]. The safety of this approach requires further study given concerns related to renal toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Effect of lamivudine cotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in patients who developed lamivudine resistance decreases the emergence of genotypic resistance to adefovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/18,23,45\">",
"     18,23,45",
"    </a>",
"    ]. In a summary of three studies of adefovir in patients with lamivudine-resistant HBV, adefovir resistance was detected in four patients only, all of whom had stopped lamivudine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/23\">",
"     23",
"    </a>",
"    ], suggesting that continuation of lamivudine is important in preventing the development of sequential resistance to adefovir. Similarly, the development of adefovir resistance was associated with switching from lamivudine monotherapy to adefovir monotherapy in another series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/18\">",
"     18",
"    </a>",
"    ]. Adefovir resistance was observed in 5 of 18 patients (28 percent) who were switched to adefovir monotherapy compared with none of 16 who continued to receive lamivudine plus adefovir.",
"   </p>",
"   <p>",
"    Combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    also appears to reduce resistance to lamivudine when both drugs are given to patients who have never received treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12760?source=see_link\">",
"     \"Combination therapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Susceptibility of adefovir-resistant HBV to other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro and human studies showed that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    -resistant HBV mutants are susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36792/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the duration of benefit is unknown and may be short-lived in patients with prior lamivudine resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .) In vitro studies showed that adefovir-resistant HBV mutants have diminished susceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . The initial decline in serum HBV DNA levels observed when patients with adefovir-resistant HBV are switched to tenofovir is likely related to the higher dose of tenofovir used in clinical practice. Adefovir-resistant HBV mutations persist after switching to tenofovir, and suppression of serum HBV DNA to undetectable levels rarely occurs after switching to tenofovir monotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conclusions summarize the results of the data described above:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      (10 mg daily for 48 weeks) in patients with HBeAg positive or HBeAg negative chronic HBV infection was associated with a 3 to 4 log10 reduction in mean HBV DNA levels. The degree of reduction in HBV DNA is less than what has been observed in studies with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (5 to 7 log10 reduction in mean HBV DNA levels), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (4 to 5 log10 reduction in mean HBV DNA levels). We suggest alternative therapy such as switching to tenofovir for patients with a suboptimal virologic response (HBV DNA more than 4 log",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      after 6 to 12 months of adefovir (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In countries where tenofovir is approved, adefovir should not be used as initial therapy because of its weak antiviral activity.",
"     </li>",
"     <li>",
"      Significant improvements in liver histology and serum ALT levels were observed in all patient groups studied (ie, HBeAg positive and negative,",
"      <span class=\"nowrap\">",
"       HBV/HIV",
"      </span>",
"      coinfection,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      resistance, and post-liver transplant).",
"     </li>",
"     <li>",
"      HBeAg seroconversion (loss of HBeAg and gain of anti-HBe) was observed in 12 percent of patients after one year of treatment, with further increase to an estimate of 48 percent after five years of continued treatment.",
"     </li>",
"     <li>",
"      In HBeAg negative patients, approximately 55 percent have maintained viral suppression after four to five years of continued treatment.",
"     </li>",
"     <li>",
"      In patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      -resistant chronic HBV infection, a similar degree of HBV DNA suppression was observed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      monotherapy as with combination therapy with adefovir and lamivudine (100 mg daily). However, combination therapy is associated with a lower risk of adefovir resistance and is preferred in patients who require long-term treatment. In countries where",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      is available, a switch to or the addition of tenofovir is preferred to adefovir because of its more potent antiviral activity.",
"     </li>",
"     <li>",
"      The optimal duration of therapy is uncertain. We suggest continued treatment in patients with HBeAg positive chronic hepatitis who have not seroconverted but have continued viral suppression until 12 months after achievement of HBeAg seroconversion (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest continuing treatment for at least four to five years in patients with HBeAg negative chronic hepatitis who continue to have suppression of HBV DNA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      An approach to treatment of HBV that considers all the available treatment options in various settings is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link\">",
"       \"Overview of the management of hepatitis B and case examples\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/1\">",
"      Gilson RJ, Chopra KB, Newell AM, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999; 6:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/2\">",
"      Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/3\">",
"      Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/4\">",
"      Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006; 44:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/5\">",
"      Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/6\">",
"      Wu IC, Shiffman ML, Tong MJ, et al. Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. Clin Infect Dis 2008; 47:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/7\">",
"      Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/8\">",
"      Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/9\">",
"      Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/10\">",
"      Lampertico P, Vigano M, Mamenti E, et al. Five years of sequential LAM to LAM + ADV therapy suppresses HBV replication in most HBeAg-negative cirrhosits, preventing decompensation but not hepatocellular carcinoma (abstract). J Hepatol 2006; 44 (Suppl2:)S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/11\">",
"      Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/12\">",
"      Shiffman M, Marcellin P, Jeffers L, et al. HBsAg seroconversion in adefovir dipivoxil treated chronic hepatitis B patients (abstract). J Hepatol 2004; 40(Suppl 1):17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/13\">",
"      Xiong X, Flores C, Yang H, et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/14\">",
"      Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/15\">",
"      Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/16\">",
"      Peters MG, Hann Hw Hw, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/17\">",
"      Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/18\">",
"      Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/19\">",
"      Lok AS, Han SH, Chung R, et al. Virological response and resistance to adefovir (ADV) therapy in liver transplant (OLT) patients (abstract). Hepatology 2005; 42(Suppl 1):232A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/20\">",
"      Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/21\">",
"      Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/22\">",
"      Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/23\">",
"      Snow A, Thibault V, Qi X, et al. Combination of adefovir dipivoxil and lamivudine prevented emergence of adefovir resistance mutations in chronic hepatitis B patients with lamivudine-resistant HBV (abstract). Gastroenterology 2005; (Suppl).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/24\">",
"      Lampertico P, Marzano A, Levero M, et al. A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 20 year analysis of 650 patients (abstract). J Hepatol 2006; 44 (Suppl 2):S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/25\">",
"      Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B (abstract). Hepatology 2006; 44 (Suppl 1):693A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/26\">",
"      Lampertico P, Vigano M, Manenti E, et al. 3 years of adefovir and lamivudine combination therapy minimizes the risk of genotypic resistance to adv and lam resistant patients (abstract). J Hepatol 2007; 46 (Suppl 1):S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/27\">",
"      Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HB2A-negative chronic hepatitis B (abstract). J Hepatol 2007; 46 (Suppl 1):S2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/28\">",
"      Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/29\">",
"      Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/30\">",
"      Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012; 35:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/31\">",
"      Yang H, Westland CE, Delaney WE 4th, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/32\">",
"      Westland CE, Yang H, Delaney WE 4th, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/33\">",
"      Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/34\">",
"      Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/35\">",
"      Lacombe K, Ollivet A, Gozlan J, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006; 20:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/36\">",
"      Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007; 47:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/37\">",
"      Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/38\">",
"      Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/39\">",
"      Curtis M, Zhu Y, Borroto-Esoda K, et al. HBV RTI233V polymerase variant remains sensitive to adefovir (abstract). J Hepatol 2007; 46 (Suppl 1):S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/40\">",
"      Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil therapy for patients with chronic hepatitis B (abstract). J Hepatol 2005; 42 (Suppl 2):17A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/41\">",
"      Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/42\">",
"      Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/43\">",
"      Carrou&eacute;e-Durantel S, Durantel D, Werle-Lapostolle B, et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther 2008; 13:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/44\">",
"      H&eacute;zode C, Chevaliez S, Bouvier-Alias M, et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol 2007; 46:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36792/abstract/45\">",
"      Gaia S, Barbon V, Smedile A, et al. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 2008; 48:540.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3648 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36792=[""].join("\n");
var outline_f35_59_36792=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HBeAg POSITIVE CHRONIC HEPATITIS B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Durability of HBeAg seroconversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HBeAg NEGATIVE CHRONIC HEPATITIS B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adefovir monotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HBsAg LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATIENTS WITH LAMIVUDINE RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Liver transplantation and decompensated liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Compensated liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HIV coinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DEVELOPMENT OF RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recognition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Effect of lamivudine cotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Susceptibility of adefovir-resistant HBV to other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12760?source=related_link\">",
"      Combination therapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=related_link\">",
"      Entecavir in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_59_36793="Management and outcome of D-transposition of the great arteries";
var content_f35_59_36793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management and outcome of D-transposition of the great arteries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/59/36793/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/59/36793/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/59/36793/contributors\">",
"     David A Kane, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/59/36793/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/59/36793/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/59/36793/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/59/36793/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/59/36793/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H947938\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transposition of the great arteries (TGA) is a ventriculoarterial discordant lesion, in which the aorta arises from the right ventricle and the pulmonary artery from the left ventricle. The most common form of TGA is the dextro type (referred to as D-TGA), in which the ventricles are oriented so that the right ventricle is positioned to the right of the left ventricle and the origin of the aorta is anterior and rightward to the origin of the pulmonary artery (",
"    <a class=\"graphic graphic_figure graphicRef68589 \" href=\"mobipreview.htm?12/51/13106\">",
"     figure 1",
"    </a>",
"    ). The anatomical defect of D-TGA leads to cyanotic heart disease as a result of two parallel circulations. The first sends deoxygenated systemic venous blood to the right atrium and back to the systemic circulation via the right ventricle and aorta, and the second sends oxygenated pulmonary venous blood to the left atrium and back to the lungs via the left ventricle and pulmonary artery.",
"   </p>",
"   <p>",
"    The survival of patients with D-TGA has dramatically improved from a uniformly fatal disease with introduction of initial medical management consisting of prostaglandin (also known as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/57/23445?source=see_link\">",
"     alprostadil",
"    </a>",
"    ) therapy and balloon atrial septostomy (BAS), and the development of corrective surgical procedures.",
"   </p>",
"   <p>",
"    The management and outcome of D-TGA will be presented here. The pathophysiology, clinical features, and diagnosis of D-TGA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/8/25735?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H948619\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management is focused on stabilization of cardiac and pulmonary function and ensuring adequate systemic oxygenation. Therapy is directed towards providing sufficient intercirculatory mixing between the two parallel circulations by maintaining patency of the ductus arteriosus with prostaglandin E1 (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/57/23445?source=see_link\">",
"     alprostadil",
"    </a>",
"    ) infusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    balloon atrial septostomy (BAS).",
"   </p>",
"   <p>",
"    Once the infant is stabilized, corrective surgery is optimally performed in the first weeks of life.",
"   </p>",
"   <p>",
"    The prenatal diagnosis of D-TGA improves survival as it allows for delivery at a tertiary center, where pediatric cardiologists can make timely postnatal decisions regarding prostaglandin (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/57/23445?source=see_link\">",
"     alprostadil",
"    </a>",
"    ) infusion and the need for a BAS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/1\">",
"     1",
"    </a>",
"    ]. However, D-TGA is one of the more difficult congenital heart diseases to be diagnosed prenatally and, therefore, most infants present postnatally. Patients with suspected or confirmed D-TGA should be transported as quickly as possible to an institution that has expertise in managing infants with D-TGA. Prior to transport, consultation with a pediatric cardiologist is necessary to ensure optimal medical management before and during the transfer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/8/25735?source=see_link&amp;anchor=H4432983#H4432983\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H948657\">",
"    <span class=\"h2\">",
"     Prostaglandin (alprostadil) infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;After consultation with a pediatric cardiologist, continuous intravenous (IV) prostaglandin E1 infusion (0.05",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per minute) is used to maintain patency of the ductus arteriosus in neonates, in whom the diagnosis of D-TGA is suspected or confirmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/2\">",
"     2",
"    </a>",
"    ]. A patent ductus arteriosus promotes intercirculatory mixing.",
"   </p>",
"   <p>",
"    The major side effect of prostaglandin (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/57/23445?source=see_link\">",
"     alprostadil",
"    </a>",
"    ) is apnea, and intubation should be considered prior to transport to a pediatric cardiac center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/3\">",
"     3",
"    </a>",
"    ]. Vasodilation may cause hypotension, which is corrected with volume expansion using intravenous isotonic saline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4434705\">",
"    <span class=\"h2\">",
"     Balloon atrial septostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important role for cardiac catheterization in D-TGA is to perform a balloon atrial septostomy (BAS). Introduced in 1966, this procedure dramatically increased the survival of infants with D-TGA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/4\">",
"     4",
"    </a>",
"    ]. BAS now is performed to stabilize patients with severe hypoxemia as a consequence of inadequate mixing between the two parallel circuits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. It can be performed at the bedside with echocardiographic guidance, or in the catheterization lab with the use of fluoroscopy and echocardiography. A balloon is placed across the atrial septum into the left atrium either through cannulation of the umbilical vein or percutaneous access of the femoral vein. The balloon is inflated and then pulled vigorously back across the septum. The procedure is repeated at least once, and then echocardiographic and hemodynamic assessment of the defect is performed to ensure intracardiac mixing is adequate for sufficient systemic oxygenation.",
"   </p>",
"   <p>",
"    If a BAS is performed and successful, systemic oxygen saturations should begin to increase immediately. If there is adequate mixing at the atrial level, prostaglandin (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/57/23445?source=see_link\">",
"     alprostadil",
"    </a>",
"    ) infusion can often be discontinued as long as there is no concern regarding aortic arch obstruction.",
"   </p>",
"   <p>",
"    Brain injury has been raised as a potential complication of BAS. This is based on the theory that patients with D-TGA are at increased risk for cerebral emboli during catheterization as the systemic venous return is in direct communication with the aorta and cerebral arterial circulation. However, the data are inadequate to support an association with BAS and an increased risk of brain injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 29 infants with D-TGA, 12 had evidence of brain injury on preoperative MRI that included focal ischemic changes suggestive of arterial emboli [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/7\">",
"       7",
"      </a>",
"      ]. All 12 patients had a BAS, and none of the 10 patients who did not undergo BAS had evidence of preoperative brain injury. However, this study did not control for the degree of hypoxemia, an indication for BAS, and a potential confounding variable for brain injury.",
"     </li>",
"     <li>",
"      Subsequent studies of neonates with D-TGA have reported a lower incidence of focal ischemia and found no association between BAS and brain injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 64 neonates with CHD including 44 with TGA, brain injury, predominantly white matter injury, occurred in 19 patients (30 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/8\">",
"       8",
"      </a>",
"      ]. There was no association between BAS and brain injury in infants with D-TGA. The rates and patterns of brain injury were similar in infants with D-TGA compared to those with other complex CHD (eg, hypoplastic left heart syndrome and pulmonary atresia).",
"     </li>",
"     <li>",
"      In a study of 26 infants with D-TGA including 14 who underwent BAS, 10 patients had periventricular leukomalacia (PVL) due to hypoxia and no patients had evidence of a thromboembolic cerebrovascular accident [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/9\">",
"       9",
"      </a>",
"      ]. Patients with PVL were more likely to have lower preoperative oxygenation (measured by pulse oximetry and arterial blood gas testing), and a longer time to surgery than those without PVL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of these studies suggest that multiple factors are associated with brain injury, particularly the degree and duration of hypoxemia. Despite these results, our practice is to administer a bolus dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     units/kg)",
"    </span>",
"    prior to performing BAS to minimize thrombus formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2923554\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality of D-TGA has dramatically improved from 90 percent for unoperated patients to rates of less than 5 percent following corrective surgery using the arterial switch operation (ASO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/3,10\">",
"     3,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our current practice, most patients are referred for surgical repair during the first three to five days of life. The choice of surgical procedure is dependent on the presence and nature of other cardiac anomalies. Our general approach is as follows, although, the ultimate choice is decided on an individual setting based on the anatomical features of the patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients without any other cardiac defect (simple D-TGA), arterial switch operation (ASO) is the recommended procedure. In general, the ASO has replaced the earlier atrial switch procedures developed by Mustard and Senning.",
"     </li>",
"     <li>",
"      In patients with D-TGA and a ventricular septal defect (VSD), the preferred procedure is ASO and VSD closure.",
"     </li>",
"     <li>",
"      In patients with D-TGA, large VSD, and significant pulmonary stenosis, the Rastelli procedure, an alternative surgical approach, should be considered. In some cases, ASO with or without repair of the left ventricular outflow obstruction is used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both the ASO and Rastelli procedures are surgical anatomic corrections resulting in a morphologic left ventricle as the systemic ventricle. In comparison to atrial switch procedures, which involved the rerouting of venous return in the atria and are now only rarely performed, the arterial switch operation appears to have similar long-term survival rates with reduced long-term morbidity primarily due to a lower risk of atrial arrhythmias and heart failure. As a result, it is the recommended procedure in most patients with D-TGA. (See",
"    <a class=\"local\" href=\"#H88581680\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5811268\">",
"    <span class=\"h2\">",
"     Arterial switch operation (ASO)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial switch operation (ASO), originally performed in 1975, has become the standard corrective procedure for patients with D-TGA who do not have significant left ventricular outflow obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/12\">",
"     12",
"    </a>",
"    ]. It has supplanted the atrial switch procedures (also referred to as the Mustard and Senning procedures) because of their long-term complications including atrial arrhythmias and right ventricular failure. At the Children&rsquo;s Hospital in Boston, the ASO has been used as the preferred procedure for patients with D-TGA since 1988 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/3\">",
"     3",
"    </a>",
"    ]. The overall perioperative mortality with the ASO has dropped to nearly 0 percent in patients with simple D-TGA (ie, no other cardiac anomaly) and 4 percent for those with complex D-TGA (ie, additional cardiac anomaly) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/8/25735?source=see_link&amp;anchor=H2924878#H2924878\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries\", section on 'Other cardiac anomalies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ASO involves transection of both great arteries, and then translocation of the vessels to the opposite root, thereby creating ventriculoarterial concordance (aorta to left ventricle, and pulmonary artery to right ventricle). Translocating the aorta also involves mobilization and reimplantation of the coronary arteries. In the ASO, &ldquo;buttons&rdquo; around the coronaries are created and then reimplanted into the neo-aortic root. As a result, it is important to delineate coronary artery anatomy, which is often aberrant, prior to surgical correction (",
"    <a class=\"graphic graphic_figure graphicRef60625 \" href=\"mobipreview.htm?10/53/11097\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/8/25735?source=see_link&amp;anchor=H2924878#H2924878\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries\", section on 'Other cardiac anomalies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Lecompte maneuver, first described in 1981, is widely utilized when performing the ASO. This surgical technique places the bifurcation of the pulmonary arteries anterior to the aorta so that the left and right pulmonary arteries straddle the ascending aorta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/13\">",
"     13",
"    </a>",
"    ]. This allows for improved orientation of the branch pulmonary arteries and reduces the tension that is created from the anterior translocation of the pulmonary arterial root. The use of this maneuver decreases the risk of subsequent pulmonary artery stenosis and lowers reintervention rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/10,14,15\">",
"     10,14,15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H88582048\">",
"     'Main and branch pulmonary artery stenosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The ASO is typically performed within the first two weeks of life. Delaying the procedure beyond the first months of life allows the left ventricle to pump against the lower resistance pulmonary circulation, which may result in myocardial deconditioning. In such patients, postoperative exposure of the left ventricle to an acute pressure load associated with systemic vascular resistance may cause acute ventricular failure.",
"   </p>",
"   <p>",
"    The presence of a VSD confers a higher probability of other anatomic abnormalities that make surgical correction more difficult. A complete understanding of all pre-operative anatomic details is essential, as additional surgical procedures to the ASO may be necessary, such as aortic arch or atrioventricular valve repair. In patients with particular forms of left ventricular outflow tract obstruction, the ASO may not be the preferred surgical procedure.",
"   </p>",
"   <p>",
"    Cardiac arrhythmias are unusual, and long-term studies report over 90 percent of patients are in normal sinus rhythm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/10,16,17\">",
"     10,16,17",
"    </a>",
"    ]. Echographic evaluation demonstrates normal left ventricular function in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/18\">",
"     18",
"    </a>",
"    ], and more than 95 percent of patients meet the criteria for the New York Heart Association functional class I in long-term follow-up (ie, no limitations during ordinary activity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/10,16\">",
"     10,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86102114\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up is necessary in patients who undergo ASO because complications that require reintervention occur in 5 to 14 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/16,19,20\">",
"     16,19,20",
"    </a>",
"    ]. The lesions that most often require reintervention include pulmonary artery stenosis, coronary artery insufficiency, neo-aortic root dilation, and neo-aortic regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88582048\">",
"    <span class=\"h4\">",
"     Main and branch pulmonary artery stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary artery stenosis is the most common indication for reintervention following ASO in the first year of life. Inadequate growth at the neo-pulmonary anastomotic site contributes to pulmonary stenosis. The reported incidence of operative or catheterization based reintervention ranges from 5 to 28 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, performance of the ASO in the neonatal period has reduced the need for pulmonary artery banding and the widespread use of the Lecompte maneuver have resulted in a lower incidence of pulmonary stenosis and a reduced reintervention rate of less than 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/10,14,15\">",
"     10,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to intervene typically is made as the right ventricular pressure approaches systemic levels. The level of obstruction is generally located in the supravalvar area of the main pulmonary artery, but it can be found at all levels of the right ventricular outflow tract and the branch pulmonary arteries. Supravalvar stenosis is thought to result from scarring at the anastomotic site or inadequate growth of the main pulmonary artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Branch pulmonary artery stenosis is generally a consequence of tension on the branch pulmonary arteries from their anterior translocation. Prior pulmonary artery banding, repair outside of the neonatal period, and surgical technique have been identified as risk factors.",
"   </p>",
"   <p>",
"    Echocardiography is initially used to detect and evaluate pulmonary artery stenosis, but is not as sensitive in detecting branch pulmonary artery stenosis as magnetic resonance imaging (MRI). Right ventricular pressure should always be evaluated by routine transthoracic echocardiography (TTE) in patients who have undergone ASO; if there is concern for elevated pressure and the proximal pulmonary arteries cannot be identified, alternative imaging techniques, such as MRI, should be considered to determine whether branch pulmonary artery stenosis is present. Proximal branch pulmonary artery stenosis was detected in only 60 to 70 percent of affected patients with TTE, while cardiac MRI identified closer to 90 percent of lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, evaluation for branch pulmonary artery stenosis with TTE can be difficult after the Lecompte maneuver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88582069\">",
"    <span class=\"h4\">",
"     Coronary artery stenosis or insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early years of the ASO, the coronary artery transfer was the surgical step that created the most difficulty, and led to coronary insufficiency and high hospital mortality. As surgeons began to improve coronary artery transfer techniques, the hospital mortality dropped precipitously to its current low level. The long term success of this procedure, however, depends on the continued patency and growth of the coronary vessels to ensure adequate myocardial blood flow.",
"   </p>",
"   <p>",
"    The incidence of coronary events continues to be bimodal with the majority of events (89 percent) occurring in the first three months following the ASO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/25\">",
"     25",
"    </a>",
"    ]. These tend to be related to &ldquo;kinking&rdquo; or other anatomic obstructions to coronary perfusion. Unexplained ventricular dysfunction or poor hemodynamics should prompt early evaluation of the coronaries in the postoperative setting.",
"   </p>",
"   <p>",
"    In one study of 1198 survivors after ASO born between 1982 and 2001, the freedom from coronary events was reported 92.7 percent at one year and 88.2 percent at 15 years confirming the increased risk of coronary events in the postoperative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/25\">",
"     25",
"    </a>",
"    ]. Risk factors for the development of coronary events include type of coronary anatomy (presence of a single coronary orifice or two coronary orifices originating close to each other) and the occurrence of a major intraoperative event (coronary translocation difficulty, left ventricular dysfunction, cardiac arrest, or temporary mechanical support at the end of the intervention). In this study, 11 patients underwent coronary revascularization at least one year after the ASO.",
"   </p>",
"   <p>",
"    However, many patients with coronary artery stenosis or obstruction may be asymptomatic. Coronary angiography remains the gold standard for detecting coronary lesions. Studies that performed postoperative angiography report rates of coronary lesions between 3 to 6.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/10,26-28\">",
"     10,26-28",
"    </a>",
"    ]. Unfortunately, less invasive screening tests, such as electrocardiography, echocardiography, stress tests, and myocardial scintigraphy have shown poor sensitivity for detecting coronary lesions and myocardial ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/25\">",
"     25",
"    </a>",
"    ]. This is likely due to the development of a collateral coronary circulation that provides sufficient myocardial perfusion to limit detection of ischemia on these various screening tests. Magnetic resonance and computed tomographic angiography appear to be reasonable alternatives to catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/29\">",
"     29",
"    </a>",
"    ]. Increased experience with these modalities will hopefully reduce the need for invasive angiography in the future in patients after ASO.",
"   </p>",
"   <p>",
"    In addition, the impact of atherosclerotic disease in patients who have undergone ASO remains unknown as the earliest survivors are still relatively young. There is a hypothetical concern that the process of coronary transfer may predispose these patients to the development of intimal thickening due to altered flow dynamics. Lifetime cardiovascular risk assessment and lipid monitoring are essential for patients with D-TGA who have undergone ASO, to try to minimize atherosclerosis and optimize cardiovascular health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88585141\">",
"    <span class=\"h4\">",
"     Neo-aortic root dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;By reversing the great arteries in the ASO, the native pulmonary valve becomes the neo-aortic valve, and over time, the neo-aortic root increases in size. In one report of 335 patients, neo-aortic root dilation (defined as a Z-score &ge;3.0) was observed in 3, 8, 18, and 49 percent of patients at 1, 2, 5, and 10 years after ASO, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/15\">",
"     15",
"    </a>",
"    ]. Although neo-aortic root dilation continued to develop in late follow-up, the increase was not clinically significant over time. Risk factors for neo-aortic root dilation were previous pulmonary arterial banding and ASO performed in a later era. A change in surgical technique is a likely explanation for the association between surgery in a more recent era with neo-aortic root dilation, possibly related to the increased size of the coronary &ldquo;buttons&rdquo; taken for the translocation. In this current era, pulmonary arterial banding is very rare as complete repairs are typically performed in the first week of life, thereby reducing the frequency of pulmonary stenosis and neo-aortic root dilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88585552\">",
"    <span class=\"h4\">",
"     Neo-aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, in ASO, the native pulmonary valve becomes the neo-aortic valve and the competence of this valve has been a concern as it functions in the setting of systemic pressure. In particular, it is unknown what the effect of developing arterial hypertension in adult survivors will have on long-term function of the neo-aortic valve. Although mild aortic regurgitation (AR) appears to be a frequent finding, it does not usually progress to clinical significance. In one study of 1,156 survivors after ASO who were operated between 1982 and 2000, 15 percent developed AR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/30\">",
"     30",
"    </a>",
"    ]. AR was mild and did not progress, as the overall rates of reoperation for AR were 2.3 and 3.2 percent at 10 and 15 years after ASO. Risk factors for AR include the presence of a ventricular septal defect and older age at the time of ASO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/15,30\">",
"     15,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were reported in another retrospective review of 479 survivors after ASO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/31\">",
"     31",
"    </a>",
"    ]. At a mean follow-up of 9.3 years, 53 percent of patients had no AR, 38 percent had trivial AR, 7 percent had mild AR, and 2 percent had moderate AR. Aortic valve replacement was performed in 11 patients (2.2 percent) at a mean time of 11.2 years after ASO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5811275\">",
"    <span class=\"h2\">",
"     Rastelli procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Rastelli procedure, first described in 1969, is typically performed in patients with a large VSD and pulmonary stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/32\">",
"     32",
"    </a>",
"    ]. In this operation, there is no attempt to resect the left ventricular outflow tract obstruction (ie, pulmonary stenosis). The procedure entails closing the VSD by a baffle so that the oxygenated blood from the left ventricle is directed into the aorta, and placing a conduit from the right ventricle to the pulmonary artery. The net result is oxygenated blood from the left ventricle flows into the aorta, and the unoxygenated blood from the right ventricle is sent through the conduit into the pulmonary artery.",
"   </p>",
"   <p>",
"    The Rastelli procedure requires a sizable and appropriately located VSD so that the baffle can be placed to redirect blood flow into the aorta. In some patients with a restrictive VSD, the defect is enlarged for appropriate baffle placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/33\">",
"     33",
"    </a>",
"    ]. VSD enlargement may contribute to late ventricular dysfunction, arrhythmia, and residual VSD.",
"   </p>",
"   <p>",
"    Long-term, patients who undergo the Rastelli procedure require serial conduit replacements as conduits become stenosed over time as they do not grow with the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, atrial and ventricular arrhythmias are more frequent, and right and left ventricular failure may occur.",
"   </p>",
"   <p>",
"    In one case series of 40 patients with D-TGA, VSD and pulmonary stenosis who underwent Rastelli operation between 1988 and 2008, there were no perioperative deaths following the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/34\">",
"     34",
"    </a>",
"    ]. After a mean follow-up of 8.6 years, there were three late deaths, one patient underwent cardiac transplantation, and one patient was lost to follow-up. Sixteen patients (40 percent) required reoperation for conduit stenosis, and two for left ventricular outflow tract obstruction.",
"   </p>",
"   <p>",
"    In a series of 53 patients with D-TGA from Children&rsquo;s Hospital in Boston who underwent a Rastelli procedure between 1988 and 2002, a similar low mortality rate of 8 percent was seen at follow-up 18 months after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other surgical alternatives to address forms of D-TGA, VSD, and pulmonary stenosis include the Nakaidoh procedure, R&eacute;paration &agrave; l&rsquo;Etage ventriculaire (REV) procedure, and the Yasui procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/35\">",
"     35",
"    </a>",
"    ]. However, these surgeries are less commonly performed and their procedural details are beyond the scope of this chapter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2923569\">",
"    <span class=\"h2\">",
"     Atrial switch procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial switch procedures including the Mustard and Senning procedures convert the parallel circulations of D-TGA into a circulation in series, thereby correcting cyanosis. However, they do not correct the underlying ventriculoarterial discordance of the aorta arising from the right ventricle and the pulmonary artery from the left ventricle (",
"    <a class=\"graphic graphic_figure graphicRef50524 \" href=\"mobipreview.htm?16/11/16561\">",
"     figure 3",
"    </a>",
"    ). In both procedures, an intra-atrial baffle is created to divert the deoxygenated systemic venous return through the mitral valve to the left ventricle, and into the pulmonary circulation via the pulmonary artery. Simultaneously, the baffle directs oxygenated pulmonary venous return across the tricuspid valve to the right ventricle and subsequently to the aorta and the systemic circulation. Although the Mustard and Senning procedures have low early operative mortality, there are long-term sequelae including atrial arrhythmias and heart failure that are associated with late morbidity and mortality. These complications are related to the morphologic right ventricle serving as the pump for the systemic circulation. As a result the atrial switch procedures have been supplanted by the arterial switch operation (ASO).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88587238\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up is necessary in patients who undergo atrial switch procedures because of the risk of complications including right ventricular failure, arrhythmias, and baffle-related sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88587302\">",
"    <span class=\"h4\">",
"     Right ventricular failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial switch procedures provide physiological correction; however, they are not anatomically correct and place the right ventricle and tricuspid valve into the systemic circulation. Although all patients undergoing an atrial switch procedure develop right ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], some progress to late systemic (right) ventricular failure, which can result in death or serious morbidity requiring reoperation and possibly cardiac transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88587425\">",
"    <span class=\"h4\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial arrhythmias are common complications of the atrial switch repairs that may lead to significant morbidity and mortality in adulthood. In several long-term follow-up studies, about one-half to two-thirds of patients remain in sinus rhythm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. The remaining patients have a variety of arrhythmias including sinus node dysfunction, atrial flutter and fibrillation, and ventricular tachycardia. The loss of sinus rhythm is felt to precipitate further dysfunction in the systemic right ventricle and can lead to worsening heart failure and sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/40,42\">",
"     40,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arrhythmias may be caused by the presence of numerous atrial suture lines or from long-standing atrial enlargement due to right ventricular dysfunction or tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88587718\">",
"    <span class=\"h4\">",
"     Baffle-associated complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baffle-associated complications include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstruction at the right atrial and superior vena caval junction is a recognized complication of the Mustard procedure. The clinical presentation may include chylothorax, upper extremity edema, or facial plethora.",
"     </li>",
"     <li>",
"      Pulmonary venous obstruction is a complication more commonly associated with the Senning procedure. Pulmonary venous congestion may be an early manifestation. Progressive obstruction may be seen later and may present with symptoms of reactive airway disease.",
"     </li>",
"     <li>",
"      Baffle leaks are uncommon and generally occur at the superior aspect of the right atrium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2923605\">",
"    <span class=\"h2\">",
"     Follow-up care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing follow-up care is required in all patients with D-TGA by a cardiologist with expertise in congenital heart disease. Clinicians need to know the potential complications following the various surgical repairs. Follow-up care includes a focused history, physical examination and detailed imaging study by echocardiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI.",
"   </p>",
"   <p>",
"    The history includes asking about the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodes of syncope or palpitations that may suggest an underlying arrhythmia (See",
"      <a class=\"local\" href=\"#H88587425\">",
"       'Arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increasing exercise intolerance suggestive of declining systemic ventricular function or increasing pulmonary artery obstruction (See",
"      <a class=\"local\" href=\"#H88582048\">",
"       'Main and branch pulmonary artery stenosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H88587302\">",
"       'Right ventricular failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exertional chest pain may suggest coronary artery insufficiency (See",
"      <a class=\"local\" href=\"#H88582069\">",
"       'Coronary artery stenosis or insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Edema of the face and upper extremities suggest superior venal caval obstruction due to a baffle complication seen in the Mustard procedure (See",
"      <a class=\"local\" href=\"#H88587718\">",
"       'Baffle-associated complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vital signs particularly the pulse to determine any irregularity that suggests an underlying arrhythmia",
"     </li>",
"     <li>",
"      Cardiac auscultation to detect any murmur (eg, pulmonary stenosis, aortic or tricuspid insufficiency) or gallop (eg, failure)",
"     </li>",
"     <li>",
"      Examination for signs of cardiac failure including pulmonary congestion (rales), peripheral edema, and hepatomegaly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the following tests are routinely performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrocardiography and Holter monitoring are performed routinely to detect and diagnose arrhythmias. The electrocardiogram can also be used to screen for ischemic changes, but its sensitivity to detect coronary insufficiency is poor.",
"     </li>",
"     <li>",
"      Routine echocardiography is used to assess ventricular function, detect pulmonary artery stenosis, and evaluate competency of the neo-aortic valve. If there are historical features suggestive of ischemia or signs of unexplained depressed function on echocardiography, coronary artery insufficiency must be considered. Angiography remains the preferred modality to diagnose coronary artery occlusions in patients who undergo the arterial switch operation.",
"     </li>",
"     <li>",
"      Risk assessment for atherosclerosis and lipid monitoring as patients who undergo ASO may be more likely to develop early coronary artery disease. (See",
"      <a class=\"local\" href=\"#H88582069\">",
"       'Coronary artery stenosis or insufficiency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=see_link&amp;anchor=H10#H10\">",
"       \"Diseases associated with atherosclerosis in childhood\", section on 'Congenital heart disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis for subacute bacterial endocarditis is not required in patients who have undergone ASO and do not have any residual lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88584062\">",
"    <span class=\"h3\">",
"     Activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 36th Bethesda conference provides exercise and athletic participation guidelines for patients with congenital heart disease. Patients who have undergone an ASO and have no residual defects, normal ventricular function, a normal exercise test, and have no evidence of atrial or ventricular tachyarrhythmias may participate in all competitive sports without restrictions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88581680\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall outcome for patients with D-TGA has dramatically improved from a uniformly fatal disease in untreated patients to long-term survival rates of greater than 90 percent due to advances in initial management and surgical correction. However, survivors are at risk for significant morbidity that may require further surgical intervention. The arterial switch operation (ASO) is currently the preferred surgical procedure as it appears to have the best long-term survival, morbidity, and functional outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88581687\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term survival rates for patients with D-TGA following surgical correction are excellent for both ASO and atrial switch procedures. Although there have been no clinical trials comparing the different surgical approaches, a review of long-term outcome from a single tertiary center in Germany reported improved long-term survival when the center changed from the Mustard and Senning atrial switch procedures to the ASO in 1983 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/44\">",
"     44",
"    </a>",
"    ]. Although perioperative mortality rates were similar (6, 5, and 8 percent for ASO, Senning procedure, and Mustard procedure, respectively), long-term survival rates 20 years after discharge were 97, 93, and 82 percent for the ASO, Senning procedure, and Mustard procedures, respectively.",
"   </p>",
"   <p>",
"    Similar excellent long-term outcomes after ASO of greater than 95 percent survival at 20 and 25 years following discharge have been reported from a number of centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/10,14,16,45\">",
"     10,14,16,45",
"    </a>",
"    ]. In contrast, long-term survival of the Mustard atrial switch procedure is approximately 80 percent at 20 years and 75 percent at 25 years following discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/40\">",
"     40",
"    </a>",
"    ]. Progressive congestive heart failure and sudden death are the principal causes of death.",
"   </p>",
"   <p>",
"    Perioperative mortality is greater in patients with complex (additional cardiac anomaly) D-TGA compared to those with simple D-TGA (no other cardiac anomaly) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/3,14,19,23,46-48\">",
"     3,14,19,23,46-48",
"    </a>",
"    ]. Other reported predictors of mortality include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prematurity &lt;36 weeks gestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Low birth weight",
"      <sup>",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intramural or single coronary artery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/49\">",
"       49",
"      </a>",
"      ]; however, multiple groups have not demonstrated increased mortality risks based on coronary anatomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/14,19,46\">",
"       14,19,46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Aortic arch obstruction",
"     </li>",
"     <li>",
"      Right ventricular hypoplasia",
"      <sup>",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173621864\">",
"    <span class=\"h2\">",
"     Long-term morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials comparing outcomes of ASO and atrial switch procedures. Reintervention is common following both approaches as indicated by the following studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort of 65 patients with an ASO performed before 1991, 11 (17 percent) had one clinically significant cardiac lesion including ventricular dysfunction, valvular dysfunction or arrhythmias at follow-up at a mean age of 21 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/16\">",
"       16",
"      </a>",
"      ]. Almost 40 percent required reintervention primarily for right ventricular outflow tract obstruction (17 of 24 reoperations). However, the introduction of the Lecompte maneuver decreased the need for reoperation to 15 percent.",
"     </li>",
"     <li>",
"      In another study of 151 survivors with an ASO performed before 2000, the most common complications were pulmonary stenosis (requiring 45 reinterventions in 25 patients), left ventricular dysfunction (n = 5), coronary artery sequelae in 5 of 61 patients who underwent angiography, arrhythmias (n = 5 including 2 with ventricular fibrillation, 1 each with sick sinus, atrial flutter, and a single episode of supraventricular tachycardia), and moderate (n = 1) and severe (n = 1) neo-aortic regurgitation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 88 patients following a Mustard procedure, follow-up at a mean of 21 years for 80 survivors demonstrated 71 percent survival rate without a need for reoperation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/39\">",
"       39",
"      </a>",
"      ]. There were a total of 31 reoperations that include 7 for systemic ventricular failure and 24 for baffle complications. (See",
"      <a class=\"local\" href=\"#H88587718\">",
"       'Baffle-associated complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88584017\">",
"    <span class=\"h2\">",
"     Functional status",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173622193\">",
"    <span class=\"h3\">",
"     Exercise capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo surgical repair for D-TGA have a reduced exercise capacity primarily due to pulmonary disease. In one follow-up study, patients 12 years of age after ASO, had lower peak oxygen consumption during exercise compared to normal control patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, 2 of the 42 patients had abnormal myocardial perfusion during exercise detected by radionuclide perfusion imaging.",
"   </p>",
"   <p>",
"    Patients after ASO appear to have better exercise capacity than those who underwent atrial switch procedures. This was illustrated in a study that compared exercise in normal patients without congenital heart disease with those patients with D-TGA who have undergone arterial switch and those who underwent an atrial switch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients after ASO had low-normal cardiorespiratory exercise capability, which was superior to that seen in patients with atrial switch procedures.",
"   </p>",
"   <p>",
"    The decrease in exercise capacity, however, does not limit ordinary activity as most patients meet the criteria for New York Heart Association functional class I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/10,16\">",
"     10,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173622265\">",
"    <span class=\"h3\">",
"     Neurodevelopmental outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series suggest that survivors after ASO are more likely than normal controls to have neurologic impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/52-57\">",
"     52-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was best illustrated in the largest case series that evaluated 139 of 159 eligible adolescents who underwent ASO as infants with neuropsychological testing at 16 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/57\">",
"     57",
"    </a>",
"    ]. Academic achievement, memory, executive function, visual-spatial skills, attention, and social cognition were assessed. The following findings were note:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In this cohort, 65 percent had a history of special educational services including tutoring, grade retention, early intervention, special education, occupational therapy, psychotherapy, and counseling.",
"     </li>",
"     <li>",
"      Although the mean scores for patients after ASO were in the normal range, the scores for all the areas tested were lower than the normative population. In an addition, a substantial number of patients after ASO had scores &ge;1 standard deviation below the expected mean.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) abnormalities were more frequently seen in the ASO group compared with a reference group of normal adolescents (33 versus 4 percent). MRI abnormality was not significantly associated with any of the selected test scores.",
"     </li>",
"     <li>",
"      In a multiple regression analysis, postoperative seizures were associated with lower scores for all the areas tested except for attention. Other factors including demographic characteristics, socioeconomic status, sex, ethnicity, preoperative factors, birth weight, age at surgery, and operations after ASO were not associated with lower testing scores.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a French prospective study of 45 children with D-TGA, patients had normal scores for cognition, language and verbal working memory at four to six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. However, children with D-TGA compared with controls had lower scores on neuropsychological tests for inhibitory control, cognitive flexibility, social cognition, and executive function. Performance in these tests also was better in patients with D-TGA diagnosed prenatally compared with those diagnosed postnatally.",
"   </p>",
"   <p>",
"    The results of these studies demonstrate the need to closely monitor the neurodevelopmental status of these patients who are at risk for impairment. We agree with the recommendations of the 2012 scientific statement from the American Heart Association that children with D-TGA undergo appropriate surveillance, screening and or referral for neurodevelopmental impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/59/36793/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=see_link\">",
"     \"Developmental-behavioral surveillance and screening in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2923654\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;D-transposition of the great arteries (D-TGA) is a ventriculoarterial discordant lesion, in which the aorta arises from the right ventricle and the pulmonary artery from the left ventricle (",
"    <a class=\"graphic graphic_figure graphicRef68589 \" href=\"mobipreview.htm?12/51/13106\">",
"     figure 1",
"    </a>",
"    ). The anatomical defect of D-TGA leads to cyanotic heart disease as a result of two parallel circulations. The first sends deoxygenated systemic venous blood to the right atrium and back to the systemic circulation via the right ventricle and aorta, and the second sends oxygenated pulmonary venous blood to the left atrium and back to the lungs via the left ventricle and pulmonary artery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The survival of patients with D-TGA has dramatically improved from a uniformly fatal disease with introduction of prostaglandin (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/57/23445?source=see_link\">",
"       alprostadil",
"      </a>",
"      ) therapy and balloon atrial septostomy (BAS), and the continued evolution of surgical palliation. (See",
"      <a class=\"local\" href=\"#H88581687\">",
"       'Survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a prenatal diagnosis of D-TGA is made or suspected, we recommend a maternal transport to a facility that has expertise in managing neonates with cyanotic congenital heart disease including D-TGA (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If this is not possible, consultation with a pediatric cardiologist prior to transport is necessary to ensure optimal medical management before and during the transfer.",
"     </li>",
"     <li>",
"      Initial post natal management is focused on stabilization of cardiac and pulmonary function and ensuring adequate systemic oxygenation. Therapy is directed towards providing sufficient intercirculatory mixing between the two circulatory systems by maintaining patency of the ductus arteriosus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend prostaglandin E1 (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/57/23445?source=see_link\">",
"       alprostadil",
"      </a>",
"      ) infusion (0.05",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      per minute) in all patients with D-TGA to maintain patency of the ductus arteriosus until adequate mixing is achieved either through BAS or surgical intervention (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H948657\">",
"       'Prostaglandin (alprostadil) infusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe hypoxemia, we recommend BAS to improve systemic oxygenation by providing adequate intercirculatory mixing (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4434705\">",
"       'Balloon atrial septostomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend surgical correction for all patients with D-TGA (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In patients with simple D-TGA , we recommend the arterial switch operation (ASO) be the preferred surgical approach versus atrial switch procedures (ie, Senning and Mustard procedures) because of its superior long-term outcome (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In patients with D-TGA and left ventricular outflow tract obstruction, the Rastelli procedure may be considered an alternate option to ASO.",
"     </li>",
"     <li>",
"      Complications of the ASO include pulmonary artery stenosis, coronary artery insufficiency, neo-aortic root dilation, and neo-aortic regurgitation. It remains unknown what effect atherosclerotic disease of the coronaries will have on patients who underwent ASO, and these patients require long-term follow-up. (See",
"      <a class=\"local\" href=\"#H86102114\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of the atrial switch procedures include right ventricular failure, arrhythmias, and baffle-associated complications (eg, superior vena caval obstruction or baffle leak). In particular, older patients who underwent atrial switch procedures are at risk for atrial arrhythmias and progressive heart failure, which are the major causes of late death. (See",
"      <a class=\"local\" href=\"#H88587238\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term follow-up care is necessary because of the potential for developing clinically significant complications following surgical repair. It entails a focused history and physical examination, and testing that includes imaging (usually echocardiography), electrocardiography, and angiography, and monitoring for atherosclerotic disease. (See",
"      <a class=\"local\" href=\"#H2923605\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term survival is excellent following surgical repair with greater than 90 percent survival after 20 years following ASO repair. (See",
"      <a class=\"local\" href=\"#H88581687\">",
"       'Survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although patients following ASO have a slightly reduced exercise capacity, this does not typically restrict their daily level of activity. (See",
"      <a class=\"local\" href=\"#H173622193\">",
"       'Exercise capacity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It appears that patients with D-TGA may have mild long-term neurodevelopmental impairment, most likely due to perioperative factors including hypoxemia, acidosis, cardiopulmonary bypass, and hemodynamic instability. (See",
"      <a class=\"local\" href=\"#H173622265\">",
"       'Neurodevelopmental outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/1\">",
"      Blyth M, Howe D, Gnanapragasam J, Wellesley D. The hidden mortality of transposition of the great arteries and survival advantage provided by prenatal diagnosis. BJOG 2008; 115:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/2\">",
"      Freed MD, Heymann MA, Lewis AB, et al. Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease. Circulation 1981; 64:899.",
"     </a>",
"    </li>",
"    <li>",
"     Fulton DR, Fyler DC. D-Transposition of the Great Arteries. In: Nadas&rsquo; Pediatric Cardiology, 2nd ed, Keane JF, Lock JE, Fyler DC (Eds), Saunders Elsevier, Philadelphia, PA 2006. p.645.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/4\">",
"      Rashkind WJ, Miller WW. Creation of an atrial septal defect without thoracotomy. A palliative approach to complete transposition of the great arteries. JAMA 1966; 196:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/5\">",
"      Hiremath G, Natarajan G, Math D, Aggarwal S. Impact of balloon atrial septostomy in neonates with transposition of great arteries. J Perinatol 2011; 31:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/6\">",
"      van der Laan ME, Verhagen EA, Bos AF, et al. Effect of balloon atrial septostomy on cerebral oxygenation in neonates with transposition of the great arteries. Pediatr Res 2013; 73:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/7\">",
"      McQuillen PS, Hamrick SE, Perez MJ, et al. Balloon atrial septostomy is associated with preoperative stroke in neonates with transposition of the great arteries. Circulation 2006; 113:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/8\">",
"      Beca J, Gunn J, Coleman L, et al. Pre-operative brain injury in newborn infants with transposition of the great arteries occurs at rates similar to other complex congenital heart disease and is not related to balloon atrial septostomy. J Am Coll Cardiol 2009; 53:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/9\">",
"      Petit CJ, Rome JJ, Wernovsky G, et al. Preoperative brain injury in transposition of the great arteries is associated with oxygenation and time to surgery, not balloon atrial septostomy. Circulation 2009; 119:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/10\">",
"      Hutter PA, Kreb DL, Mantel SF, et al. Twenty-five years' experience with the arterial switch operation. J Thorac Cardiovasc Surg 2002; 124:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/11\">",
"      Emani SM, Beroukhim R, Zurakowski D, et al. Outcomes after anatomic repair for d-transposition of the great arteries with left ventricular outflow tract obstruction. Circulation 2009; 120:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/12\">",
"      Jatene AD, Fontes VF, Paulista PP, et al. Anatomic correction of transposition of the great vessels. J Thorac Cardiovasc Surg 1976; 72:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/13\">",
"      Lecompte Y, Zannini L, Hazan E, et al. Anatomic correction of transposition of the great arteries. J Thorac Cardiovasc Surg 1981; 82:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/14\">",
"      Pr&ecirc;tre R, Tamisier D, Bonhoeffer P, et al. Results of the arterial switch operation in neonates with transposed great arteries. Lancet 2001; 357:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/15\">",
"      Schwartz ML, Gauvreau K, del Nido P, et al. Long-term predictors of aortic root dilation and aortic regurgitation after arterial switch operation. Circulation 2004; 110:II128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/16\">",
"      Tobler D, Williams WG, Jegatheeswaran A, et al. Cardiac outcomes in young adult survivors of the arterial switch operation for transposition of the great arteries. J Am Coll Cardiol 2010; 56:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/17\">",
"      Hayashi G, Kurosaki K, Echigo S, et al. Prevalence of arrhythmias and their risk factors mid- and long-term after the arterial switch operation. Pediatr Cardiol 2006; 27:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/18\">",
"      Colan SD, Trowitzsch E, Wernovsky G, et al. Myocardial performance after arterial switch operation for transposition of the great arteries with intact ventricular septum. Circulation 1988; 78:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/19\">",
"      Qamar ZA, Goldberg CS, Devaney EJ, et al. Current risk factors and outcomes for the arterial switch operation. Ann Thorac Surg 2007; 84:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/20\">",
"      Angeli E, Raisky O, Bonnet D, et al. Late reoperations after neonatal arterial switch operation for transposition of the great arteries. Eur J Cardiothorac Surg 2008; 34:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/21\">",
"      Prifti E, Crucean A, Bonacchi M, et al. Early and long term outcome of the arterial switch operation for transposition of the great arteries: predictors and functional evaluation. Eur J Cardiothorac Surg 2002; 22:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/22\">",
"      Nogi S, McCrindle BW, Boutin C, et al. Fate of the neopulmonary valve after the arterial switch operation in neonates. J Thorac Cardiovasc Surg 1998; 115:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/23\">",
"      Wernovsky G, Mayer JE Jr, Jonas RA, et al. Factors influencing early and late outcome of the arterial switch operation for transposition of the great arteries. J Thorac Cardiovasc Surg 1995; 109:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/24\">",
"      Blakenberg F, Rhee J, Hardy C, et al. MRI vs echocardiography in the evaluation of the Jatene procedure. J Comput Assist Tomogr 1994; 18:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/25\">",
"      Legendre A, Losay J, Touchot-Kon&eacute; A, et al. Coronary events after arterial switch operation for transposition of the great arteries. Circulation 2003; 108 Suppl 1:II186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/26\">",
"      Tanel RE, Wernovsky G, Landzberg MJ, et al. Coronary artery abnormalities detected at cardiac catheterization following the arterial switch operation for transposition of the great arteries. Am J Cardiol 1995; 76:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/27\">",
"      Raisky O, Bergoend E, Agnoletti G, et al. Late coronary artery lesions after neonatal arterial switch operation: results of surgical coronary revascularization. Eur J Cardiothorac Surg 2007; 31:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/28\">",
"      Angeli E, Formigari R, Pace Napoleone C, et al. Long-term coronary artery outcome after arterial switch operation for transposition of the great arteries. Eur J Cardiothorac Surg 2010; 38:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/29\">",
"      Ou P, Mousseaux E, Azarine A, et al. Detection of coronary complications after the arterial switch operation for transposition of the great arteries: first experience with multislice computed tomography in children. J Thorac Cardiovasc Surg 2006; 131:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/30\">",
"      Losay J, Touchot A, Capderou A, et al. Aortic valve regurgitation after arterial switch operation for transposition of the great arteries: incidence, risk factors, and outcome. J Am Coll Cardiol 2006; 47:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/31\">",
"      Lange R, Cleuziou J, H&ouml;rer J, et al. Risk factors for aortic insufficiency and aortic valve replacement after the arterial switch operation. Eur J Cardiothorac Surg 2008; 34:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/32\">",
"      Rastelli GC, Wallace RB, Ongley PA. Complete repair of transposition of the great arteries with pulmonary stenosis. A review and report of a case corrected by using a new surgical technique. Circulation 1969; 39:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/33\">",
"      Navabi MA, Shabanian R, Kiani A, Rahimzadeh M. The effect of ventricular septal defect enlargement on the outcome of Rastelli or Rastelli-type repair. J Thorac Cardiovasc Surg 2009; 138:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/34\">",
"      Brown JW, Ruzmetov M, Huynh D, et al. Rastelli operation for transposition of the great arteries with ventricular septal defect and pulmonary stenosis. Ann Thorac Surg 2011; 91:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/35\">",
"      Hazekamp MG, Gomez AA, Koolbergen DR, et al. Surgery for transposition of the great arteries, ventricular septal defect and left ventricular outflow tract obstruction: European Congenital Heart Surgeons Association multicentre study. Eur J Cardiothorac Surg 2010; 38:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/36\">",
"      Buch J, Wennevold A, Jacobsen JR, et al. Long-term follow-up of right ventricular function after Mustard operation for transposition of the great arteries. Scand J Thorac Cardiovasc Surg 1988; 22:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/37\">",
"      Derrick GP, Josen M, Vogel M, et al. Abnormalities of right ventricular long axis function after atrial repair of transposition of the great arteries. Heart 2001; 86:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/38\">",
"      Carrel T, Pfammatter JP. Complete transposition of the great arteries: surgical concepts for patients with systemic right ventricular failure following intraatrial repair. Thorac Cardiovasc Surg 2000; 48:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/39\">",
"      H&ouml;rer J, Herrmann F, Schreiber C, et al. How well are patients doing up to 30 years after a mustard operation? Thorac Cardiovasc Surg 2007; 55:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/40\">",
"      Oechslin E, Jenni R. 40 years after the first atrial switch procedure in patients with transposition of the great arteries: long-term results in Toronto and Zurich. Thorac Cardiovasc Surg 2000; 48:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/41\">",
"      Gelatt M, Hamilton RM, McCrindle BW, et al. Arrhythmia and mortality after the Mustard procedure: a 30-year single-center experience. J Am Coll Cardiol 1997; 29:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/42\">",
"      Gatzoulis MA, Walters J, McLaughlin PR, et al. Late arrhythmia in adults with the mustard procedure for transposition of great arteries: a surrogate marker for right ventricular dysfunction? Heart 2000; 84:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/43\">",
"      Maron BJ, Zipes DP. Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. J Am Coll Cardiol 2005; 45:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/44\">",
"      H&ouml;rer J, Schreiber C, Cleuziou J, et al. Improvement in long-term survival after hospital discharge but not in freedom from reoperation after the change from atrial to arterial switch for transposition of the great arteries. J Thorac Cardiovasc Surg 2009; 137:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/45\">",
"      Khairy P, Clair M, Fernandes SM, et al. Cardiovascular outcomes after the arterial switch operation for D-transposition of the great arteries. Circulation 2013; 127:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/46\">",
"      Blume ED, Altmann K, Mayer JE, et al. Evolution of risk factors influencing early mortality of the arterial switch operation. J Am Coll Cardiol 1999; 33:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/47\">",
"      Gottlieb D, Schwartz ML, Bischoff K, et al. Predictors of outcome of arterial switch operation for complex D-transposition. Ann Thorac Surg 2008; 85:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/48\">",
"      Sarris GE, Chatzis AC, Giannopoulos NM, et al. The arterial switch operation in Europe for transposition of the great arteries: a multi-institutional study from the European Congenital Heart Surgeons Association. J Thorac Cardiovasc Surg 2006; 132:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/49\">",
"      Pasquali SK, Hasselblad V, Li JS, et al. Coronary artery pattern and outcome of arterial switch operation for transposition of the great arteries: a meta-analysis. Circulation 2002; 106:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/50\">",
"      Sterrett LE, Schamberger MS, Ebenroth ES, et al. Myocardial perfusion and exercise capacity 12 years after arterial switch surgery for D-transposition of the great arteries. Pediatr Cardiol 2011; 32:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/51\">",
"      Reybrouck T, Eyskens B, Mertens L, et al. Cardiorespiratory exercise function after the arterial switch operation for transposition of the great arteries. Eur Heart J 2001; 22:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/52\">",
"      Karl TR, Hall S, Ford G, et al. Arterial switch with full-flow cardiopulmonary bypass and limited circulatory arrest: neurodevelopmental outcome. J Thorac Cardiovasc Surg 2004; 127:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/53\">",
"      H&ouml;vels-G&uuml;rich HH, Seghaye MC, Schnitker R, et al. Long-term neurodevelopmental outcomes in school-aged children after neonatal arterial switch operation. J Thorac Cardiovasc Surg 2002; 124:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/54\">",
"      H&ouml;vels-G&uuml;rich HH, Seghaye MC, Sigler M, et al. Neurodevelopmental outcome related to cerebral risk factors in children after neonatal arterial switch operation. Ann Thorac Surg 2001; 71:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/55\">",
"      Neufeld RE, Clark BG, Robertson CM, et al. Five-year neurocognitive and health outcomes after the neonatal arterial switch operation. J Thorac Cardiovasc Surg 2008; 136:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/56\">",
"      McGrath E, Wypij D, Rappaport LA, et al. Prediction of IQ and achievement at age 8 years from neurodevelopmental status at age 1 year in children with D-transposition of the great arteries. Pediatrics 2004; 114:e572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/57\">",
"      Bellinger DC, Wypij D, Rivkin MJ, et al. Adolescents with d-transposition of the great arteries corrected with the arterial switch procedure: neuropsychological assessment and structural brain imaging. Circulation 2011; 124:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/58\">",
"      Calderon J, Angeard N, Moutier S, et al. Impact of prenatal diagnosis on neurocognitive outcomes in children with transposition of the great arteries. J Pediatr 2012; 161:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/59\">",
"      Allen HD, Milstein JA. IQ may be normal, but are there future neurocognitive implications for infants with D-TGA? J Pediatr 2012; 161:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/59/36793/abstract/60\">",
"      Marino BS, Lipkin PH, Newburger JW, et al. Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. Circulation 2012; 126:1143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15851 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36793=[""].join("\n");
var outline_f35_59_36793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2923654\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H947938\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H948619\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H948657\">",
"      Prostaglandin (alprostadil) infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4434705\">",
"      Balloon atrial septostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2923554\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5811268\">",
"      Arterial switch operation (ASO)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86102114\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88582048\">",
"      Main and branch pulmonary artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88582069\">",
"      Coronary artery stenosis or insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88585141\">",
"      Neo-aortic root dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88585552\">",
"      Neo-aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5811275\">",
"      Rastelli procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2923569\">",
"      Atrial switch procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88587238\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88587302\">",
"      Right ventricular failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88587425\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88587718\">",
"      Baffle-associated complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2923605\">",
"      Follow-up care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88584062\">",
"      - Activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88581680\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88581687\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173621864\">",
"      Long-term morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88584017\">",
"      Functional status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173622193\">",
"      - Exercise capacity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173622265\">",
"      - Neurodevelopmental outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2923654\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/15851\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15851|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/51/13106\" title=\"figure 1\">",
"      Dextro type of transposition of the great arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/53/11097\" title=\"figure 2\">",
"      Arterial switch operation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/11/16561\" title=\"figure 3\">",
"      Atrial switch repair",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/8/25735?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_59_36794="School action plan C";
var content_f35_59_36794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    School asthma action plan (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 777px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36794=[""].join("\n");
var outline_f35_59_36794=null;
var title_f35_59_36795="Abnl findings prosthetic valves";
var content_f35_59_36795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Abnormal auscultatory findings in patients with prosthetic heart valves",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Aortic valve",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mitral valve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"2\">",
"        Caged-ball (Starr-Edwards)",
"       </td>",
"       <td>",
"        Aortic diastolic murmur",
"       </td>",
"       <td>",
"        Low frequency apical diastolic murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased intensity of opening or closing click",
"       </td>",
"       <td>",
"        High frequency holosystolic murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"2\">",
"        Single-tilting-disk (Bjork-Shiley or Medtronic-Hall)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Decreased intensity of closing click",
"       </td>",
"       <td>",
"        High frequency holosystolic murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased intensity of closing click",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"2\">",
"        Bileaflet-tilting-disk (St. Jude Medical)",
"       </td>",
"       <td>",
"        Aortic diastolic murmur",
"       </td>",
"       <td>",
"        High frequency holosystolic murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased intensity of closing click",
"       </td>",
"       <td>",
"        Decreased intensity of closing click",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Heterograft bioprosthesis (Hancock or Carpentier-Edwards)",
"       </td>",
"       <td>",
"        Aortic diastolic murmur",
"       </td>",
"       <td>",
"        High frequency holosystolic murmur",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Vongpatanasin, W, Hillis, LD, Lange, RA, N Engl J Med 1996; 335:407.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36795=[""].join("\n");
var outline_f35_59_36795=null;
var title_f35_59_36796="Causes of UGI bleeding in children";
var content_f35_59_36796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologies of upper gastrointestinal bleeding in children by age group, in approximate order of frequency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Neonate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infant",
"       </td>",
"       <td class=\"subtitle1\">",
"        Child or adolescent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swallowed maternal blood*",
"       </td>",
"       <td>",
"        Stress gastritis or ulcer",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Mallory-Weiss tear (associated with vomiting)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin K deficient bleeding",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Acid-peptic disease",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Acid-peptic disease",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stress gastritis or ulcer",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Mallory-Weiss tear (associated with vomiting)",
"       </td>",
"       <td>",
"        Gastric or esophageal varices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma (eg, nasogastric tube)",
"       </td>",
"       <td>",
"        Vascular anomalies",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Foreign body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular anomalies",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Gastrointestinal duplications",
"       </td>",
"       <td>",
"        Caustic ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulopathy (eg, associated with infection)",
"       </td>",
"       <td>",
"        Gastric or esophageal varices",
"       </td>",
"       <td>",
"        Vasculitis (eg, Henoch-Schoenlein purpura)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Milk protein intolerance",
"       </td>",
"       <td>",
"        Duodenal or gastric webs",
"       </td>",
"       <td>",
"        Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital coagulation factor deficiency",
"       </td>",
"       <td>",
"        Bowel obstruction",
"       </td>",
"       <td>",
"        Bowel obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Dieulafoy lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemobilia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     UGI: upper gastrointestinal; NSAID: non-steroidal anti-inflammatory drugs.",
"     <br>",
"      * This is a common cause of hematemesis in a newborn, and is easily confused with UGI bleeding.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Typically seen in critically ill infants.",
"       <br>",
"        &Delta; Effectively prevented by vitamin K prophylaxis which is usually given during routine neonatal care.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Especially if NSAIDs have been given.",
"         <br>",
"          &sect; Vascular anomalies include hemagiomas, telangiectasias, and other vascular malformations.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gilger MA. Upper Gastrointestinal Bleeding. In: Walker, Goulet, Kleinman, et al, Eds. Pediatric Gastrointestinal Disease, 4 Ed. B.C. Decker, Ontario, 2004. Copyright &copy; 2004 PMPH-USA, Ltd. Additional data from: Chawla S, et al, Clinical Pediatrics 2007; 46:16.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36796=[""].join("\n");
var outline_f35_59_36796=null;
var title_f35_59_36797="Triple sugar iron agar slant";
var content_f35_59_36797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shigella on triple sugar iron agar slant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 229px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Triple sugar iron agar slant shows the reaction pattern of Shigella. This pattern is designated alkaline (red) over acid (yellow), indicating the absence of lactose fermentation by the test organism. In addition, there is no gas or the black color indicative of hydrogen sulfide visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Glickman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36797=[""].join("\n");
var outline_f35_59_36797=null;
var title_f35_59_36798="Diagnostic algorithm for the diagnosis of overt DIC";
var content_f35_59_36798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm for the diagnosis of overt DIC",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 391px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Taylor FB, Toh CH, Hoots WK, et al. Towards definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation. Thromb Haemost 2001; 86:1327. Copyright &copy; 2001 Schattauer GmbH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36798=[""].join("\n");
var outline_f35_59_36798=null;
var title_f35_59_36799="Spic mass";
var content_f35_59_36799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mammogram spiculated mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spot magnification view of a mammogram showing two small adjacent interconnected spiculated masses (red arrows). Pathology revealed tubular carcinoma. Tubular carcinoma characteristically appears spiculated on mammogram and is often associated with satellite lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lisa E Esserman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_59_36799=[""].join("\n");
var outline_f35_59_36799=null;
